<SEC-DOCUMENT>0000885725-21-000056.txt : 20211123
<SEC-HEADER>0000885725-21-000056.hdr.sgml : 20211123
<ACCEPTANCE-DATETIME>20211123161316
ACCESSION NUMBER:		0000885725-21-000056
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20211119
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211123
DATE AS OF CHANGE:		20211123

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BOSTON SCIENTIFIC CORP
		CENTRAL INDEX KEY:			0000885725
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				042695240
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11083
		FILM NUMBER:		211438663

	BUSINESS ADDRESS:	
		STREET 1:		300 BOSTON SCIENTIFIC WAY
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752-1234
		BUSINESS PHONE:		508-683-4000

	MAIL ADDRESS:	
		STREET 1:		300 BOSTON SCIENTIFIC WAY
		CITY:			MARLBOROUGH
		STATE:			MA
		ZIP:			01752-1234
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bsx-20211119.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:be80d975-5a36-4151-ae87-5223c67bc7de,g:facc5304-55c5-463f-879e-772c005c0ada,d:b33b517b582442a0bdbcf7d30dabff0e--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:bsx="http://www.bostonscientific.com/20211119" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bsx-20211119</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV80L2ZyYWc6ZWM0MzhlODAzYjM1NGM2ZDliNzM5OWUxNDM5ZDIzYzIvdGFibGU6YWZiYWU3ZDFmMTNlNGY1MGJlNTg2NjEzNjA4MmExMmMvdGFibGVyYW5nZTphZmJhZTdkMWYxM2U0ZjUwYmU1ODY2MTM2MDgyYTEyY18yLTEtMS0xLTM5Nzkz_9a43e5c1-fbbb-4d46-abc9-dca751288d4d">0000885725</ix:nonNumeric><ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV80L2ZyYWc6ZWM0MzhlODAzYjM1NGM2ZDliNzM5OWUxNDM5ZDIzYzIvdGFibGU6YWZiYWU3ZDFmMTNlNGY1MGJlNTg2NjEzNjA4MmExMmMvdGFibGVyYW5nZTphZmJhZTdkMWYxM2U0ZjUwYmU1ODY2MTM2MDgyYTEyY181LTEtMS0xLTM5Nzkz_4311087e-bc6a-41c9-9134-ebc4b4dd0727">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bsx-20211119.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3c93072d72f4bb58bc058d6d4cabeef_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73fddac06dfe4a60a37ab77cd173606b_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:SeniorNotedue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe3dd1c6aa0544edbbf102eabcc07135_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib33b517b582442a0bdbcf7d30dabff0e_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">_____________________________________________________________________</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDM5_5faba540-42cb-462c-8132-db4862d07195">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">_____________________________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): (November 23, 2021) <ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8zNjQ_b15a8ca0-5173-4c02-9701-4df1df01db2e">November 19, 2021</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQw_bbfc75c8-829c-4f77-8047-949f091ad3d2">BOSTON SCIENTIFIC CORPORATION</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:31.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.073%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6M2UwNTc1NmMzYzk2NGEyYmJlOTNiOTYzM2IzNjY1NDYvdGFibGVyYW5nZTozZTA1NzU2YzNjOTY0YTJiYmU5M2I5NjMzYjM2NjU0Nl8wLTAtMS0xLTM5Nzkz_60f708c1-061e-486b-a27a-3f07cd44476f">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6M2UwNTc1NmMzYzk2NGEyYmJlOTNiOTYzM2IzNjY1NDYvdGFibGVyYW5nZTozZTA1NzU2YzNjOTY0YTJiYmU5M2I5NjMzYjM2NjU0Nl8wLTItMS0xLTM5Nzkz_02352e69-e63b-4cee-b844-67da16aca43a">1-11083</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6M2UwNTc1NmMzYzk2NGEyYmJlOTNiOTYzM2IzNjY1NDYvdGFibGVyYW5nZTozZTA1NzU2YzNjOTY0YTJiYmU5M2I5NjMzYjM2NjU0Nl8wLTYtMS0xLTM5Nzkz_69b94f7d-e424-4acd-83bf-b9d55a26e4b8">04-2695240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQ0_adea024b-fe6b-4d8e-84f0-78f5598e7482">300 Boston Scientific Way</ix:nonNumeric>, <ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQ1_db8e788a-93a2-49c9-802c-e9b2347212e7">Marlborough</ix:nonNumeric>, <ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQx_49cd3647-3a05-46e8-933b-9528177d72df">Massachusetts</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQy_988f47cd-4ac0-4092-9146-dd7227d0fbc5">01752-1234</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(Address of principal executive offices)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;             &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;   &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQ2_a429c712-3b4d-496a-aaba-d110f59c7131">508</ix:nonNumeric>) <ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQz_bc152a79-2c1f-4912-9233-af26abaf8c6c">683-4000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:1.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6ODQyYjE4OTc4ZDM5NGMwOTgzNDY1YmQyMGZmNDA4OGMvdGFibGVyYW5nZTo4NDJiMTg5NzhkMzk0YzA5ODM0NjViZDIwZmY0MDg4Y18wLTAtMS0xLTM5Nzkz_2e9a7da7-4c3a-4de1-8d9c-7e1b71345677">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6ODQyYjE4OTc4ZDM5NGMwOTgzNDY1YmQyMGZmNDA4OGMvdGFibGVyYW5nZTo4NDJiMTg5NzhkMzk0YzA5ODM0NjViZDIwZmY0MDg4Y18yLTAtMS0xLTM5Nzkz_6f186b78-571b-4a83-b031-e5cfc1c71549">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6ODQyYjE4OTc4ZDM5NGMwOTgzNDY1YmQyMGZmNDA4OGMvdGFibGVyYW5nZTo4NDJiMTg5NzhkMzk0YzA5ODM0NjViZDIwZmY0MDg4Y180LTAtMS0xLTM5Nzkz_4098541e-11a7-4324-b90a-0d6e89d5a720">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6ODQyYjE4OTc4ZDM5NGMwOTgzNDY1YmQyMGZmNDA4OGMvdGFibGVyYW5nZTo4NDJiMTg5NzhkMzk0YzA5ODM0NjViZDIwZmY0MDg4Y182LTAtMS0xLTM5Nzkz_0cdb60a0-e52b-4e31-a982-5499386683e4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3c93072d72f4bb58bc058d6d4cabeef_D20211119-20211119" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8xLTAtMS0xLTM5Nzkz_11434499-2e2b-43aa-ae2a-b233498df4bd">Common Stock, $0.01 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3c93072d72f4bb58bc058d6d4cabeef_D20211119-20211119" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8xLTItMS0xLTM5Nzkz_9d7078f1-dcf7-45b3-af3f-a067fe214330">BSX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3c93072d72f4bb58bc058d6d4cabeef_D20211119-20211119" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8xLTQtMS0xLTM5Nzkz_e0cb12dc-6a2f-4012-8428-bd4a4eba3869">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i73fddac06dfe4a60a37ab77cd173606b_D20211119-20211119" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8yLTAtMS0xLTM5Nzkz_6c607125-5e4f-4d5b-b84c-57a6f8a4f572">0.625% Senior Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i73fddac06dfe4a60a37ab77cd173606b_D20211119-20211119" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8yLTItMS0xLTM5Nzkz_5be35b91-9ce1-4999-9e62-00a8d8289514">BSX27</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i73fddac06dfe4a60a37ab77cd173606b_D20211119-20211119" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8yLTQtMS0xLTM5Nzkz_d22b5af5-8763-4281-9cb1-f584bfbe7ab7">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe3dd1c6aa0544edbbf102eabcc07135_D20211119-20211119" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8zLTAtMS0xLTM5Nzkz_27ae7736-fefb-43b9-ae55-7ceaf8608fec">5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe3dd1c6aa0544edbbf102eabcc07135_D20211119-20211119" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8zLTItMS0xLTM5Nzkz_7ef5a048-854d-468f-81ad-8f65ad3f1051">BSX PR A</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe3dd1c6aa0544edbbf102eabcc07135_D20211119-20211119" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8zLTQtMS0xLTM5Nzkz_1124b560-f795-4cde-9f1e-f623e6a2cba5">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQ3_b2e9ed05-3486-4eed-8f06-e4b22e3cc2b8">&#9744;</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ib33b517b582442a0bdbcf7d30dabff0e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.941%"><tr><td style="width:1.0%"></td><td style="width:29.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.357%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022 Annual Bonus Plan</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 19, 2021, upon the recommendation of the Executive Compensation and Human Resources Committee (the &#8220;Compensation Committee&#8221;), the Board of Directors (the &#8220;Board&#8221;) of Boston Scientific Corporation (the &#8220;Company&#8221;) approved the Company&#8217;s 2022 Annual Bonus Plan effective for the performance period January 1, 2022 through December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the Company&#8217;s overall compensation program, the 2022 Annual Bonus Plan provides an annual cash incentive opportunity for eligible exempt and nonexempt indirect labor or equivalent personnel (including the Company&#8217;s named executive officers meeting the eligibility criteria) based on the achievement of certain performance metrics. The 2022 Annual Bonus Plan provides:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for a single bonus pool (the &#8220;Total Annual Bonus&#8221;) that will be based on the Company&#8217;s performance measured against achievement of corporate-level performance goals for adjusted earnings per share; global sales as defined by the annual bonus plan, excluding the impact of foreign currency fluctuations and the impact of acquisitions and divestitures not contemplated in the annual operating plan; human capital metrics; as well as a quality assessment;</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:6.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the Total Annual Bonus, as operated, will have a ceiling of 150% of the Aggregate Annual Target, with the Board having discretion to terminate, suspend or modify the plan and to reduce the Total Annual Bonus based on the Company&#8217;s performance relative to its quality objectives and performance of its quality systems;</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the Total Annual Bonus will be allocated among corporate, global supply chain and each participating business, and region (each, a &#8220;participating unit&#8221;). For corporate and global supply chain funding units (other than manufacturing plants), funding will track to the Total Annual Bonus pool funding, within a range of 10% in either direction, depending on the CEO&#8217;s assessment of the participating unit&#8217;s performance. For businesses, regions, and manufacturing plants, funding will be based on each participating unit&#8217;s overall and relative performance measured against its achievement of that unit&#8217;s predetermined &#8220;Scorecard&#8221; performance metrics and goals and taking into consideration, as appropriate, other factors; such allocation will be a percentage of the annual bonus pool target for each participating unit (representing the total target annual bonuses of all eligible employees for the year within that unit) (each such allocated amount, an &#8220;Assigned Bonus Pool&#8221;); and</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the Assigned Bonus Pool for each participating unit will then be allocated among all managers of plan participants within that participating unit. Such managers will then evaluate the performance of the participants under their management and determine, for each participant, the percentage (between 0% and 150%) of the participant&#8217;s target annual bonus that will be used to determine the participant&#8217;s bonus award.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Awards to certain executive officers under the 2022 Annual Bonus Plan are subject to the Company&#8217;s recoupment policy, which provides that, to the extent permitted by law, the Company may seek reimbursement of a bonus award in the event of an executive officer&#8217;s misconduct or gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company.  The Company may also seek reimbursement of a bonus award if there is a restatement of the Company&#8217;s financial results that would have reduced a previously granted bonus award&#8217;s size or payment.  The amount to be recouped would be the amount of any such reduction.  Finally, if the Company determines that it is required by law to apply a &#8220;clawback&#8221; or alternate recoupment provision to a bonus award, under the Dodd-Frank Wall Street Reform and Consumer Protection Act (the &#8220;Dodd-Frank Act&#8221;) or otherwise, then such clawback or recoupment provision also will apply to the bonus award, as applicable, as if it had been included on the date the 2022 Annual Bonus Plan was established.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This description of the 2022 Annual Bonus Plan does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such plan. A copy of the 2022 Annual Bonus Plan is included in this filing as Exhibit 10.1 and incorporated herein by reference.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.883%"><tr><td style="width:1.0%"></td><td style="width:22.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.122%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022 Performance Share Programs</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 19, 2021, upon the recommendation of the Compensation Committee, the Board approved the adoption of two performance share programs, the Boston Scientific Corporation 2022 Total Shareholder Return Performance Share Program </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(the &#8220;2022 TSR PSP&#8221;) and the Boston Scientific Corporation 2022 Free Cash Flow Performance Share Program (the &#8220;2022 FCF PSP&#8221;). These programs are substantially similar to the performance share programs for 2021 and represent an important component of the overall mix of the Company&#8217;s long-term incentive program. Under both programs, performance share awards will be granted, if the relevant program criteria are met, to the Company&#8217;s executive officers in the form of restricted stock units issued under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan, which was amended and restated effective as of October 1, 2020 and which was previously approved by the Company&#8217;s stockholders. Awards to certain executive officers under both programs are subject to the Company&#8217;s recoupment policy, which provides that, to the extent permitted by law, the Company may seek recovery of performance share units in the event of an executive officer&#8217;s misconduct or gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company.  In addition, if the Company determines that it is required by law to apply a &#8220;clawback&#8221; or alternate recoupment provision to a performance share award, under the Dodd-Frank Act or otherwise, then such clawback or recoupment provision also will apply to the performance share award, as applicable, as if it had been included on the date the performance share award was granted.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.421%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(A)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2022 Total Shareholder Return Performance Share Program</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The purpose of the 2022 TSR PSP is to align the Company&#8217;s executive compensation program with the interests of stockholders and to reinforce the concept of pay for performance by comparing the Total Shareholder Return (&#8220;TSR&#8221;) of the Company&#8217;s common stock to the TSR of the other companies included in the S&amp;P 500 Healthcare Index over a three-year period beginning on January 1, 2022 and ending on December 31, 2024 (the &#8220;Performance Period&#8221;). The number of performance shares awarded will be in a range of 0% to 200% of each participant&#8217;s target number of awards based on the Company&#8217;s TSR rank. Performance share awards will vest only upon satisfaction of both the performance criteria and the payment eligibility criteria set forth in the 2022 TSR PSP, subject to certain exceptions in the event of a change of control or termination for retirement, death or disability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This description of the 2022 TSR PSP does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such program. A copy of the 2022 TSR PSP is included in this filing as Exhibit 10.2 and incorporated herein by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">     (B)       2022 Free Cash Flow Performance Share Program</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The purpose of the 2022 FCF PSP is to align the Company&#8217;s executive compensation program with the interests of stockholders and to reinforce the concept of pay for performance by providing incentives for the achievement of key business performance objectives critical to its success.  Under the 2022 FCF PSP, performance will be measured by comparing the Company&#8217;s free cash flow, as defined by the 2022 FCF PSP, for the one-year period beginning on January 1, 2022 and ending on December 31, 2022 against its 2022 financial plan performance for free cash flow, as defined by the 2022 FCF PSP. The number of performance shares awarded will be in a range of 0% to 150% of each participant&#8217;s target number of awards, depending on such performance. Performance share awards will only vest upon satisfaction of both the performance criteria and the payment eligibility criteria (which includes a three-year service period) set forth in the 2022 FCF PSP, subject to certain exceptions in the event of a change of control or termination for retirement, death or disability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This description of the 2022 FCF PSP does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such program. A copy of the 2022 FCF PSP is included in this filing as Exhibit 10.3 and incorporated herein by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.01.          FINANCIAL STATEMENTS AND EXHIBITS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;Exhibits</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 73pt;text-align:left;text-indent:-72pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101bostonscientific.htm">Boston Scientific Corporation 2022 Annual Bonus Plan, effective as of January 1, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 73pt;text-align:left;text-indent:-72pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102bostonscientific.htm">Boston Scientific Corporation 2022 Total Shareholder Return Performance Share Program</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 73pt;text-align:left;text-indent:-72pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit103bostonscientific.htm">Boston Scientific Corporation 2022 Free Cash Flow Performance Share Program</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 73pt;text-align:left;text-indent:-72pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt 0 73pt;text-indent:-72pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Documents filed or furnished with this report.</span></td></tr></table></div><div><span><br/></span></div><div id="ib33b517b582442a0bdbcf7d30dabff0e_10"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 23, 2021</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BOSTON SCIENTIFIC CORPORATION</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Vance R. Brown</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vance R. Brown</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Corporate Secretary</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101bostonscientific.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2fd60b65fd284933a2397a478bb787a3_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div><img alt="logo2021compensationplans.jpg" src="logo2021compensationplans.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:169px"></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><font style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><br></font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2022 Boston Scientific Annual Bonus Plan </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Version&#58; November 2021</font></div></td></tr></table></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">I.&#160;&#160;&#160;&#160;Establishment and Purpose of the Plan</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston Scientific Corporation has established the Boston Scientific Corporation Annual Bonus Plan (&#34;Plan&#34;).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As explained in detail below, the Plan basically works as follows. For each Performance Year, there is an Aggregate Bonus Pool, which is the sum of the bonus targets of all eligible participants.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the end of the Performance Year, the Committee determines the percentage of the pool that will be paid out as bonus for the year, based on the Company&#8217;s performance as to Global Sales, Adjusted Earnings Per Share, Human Capital Scorecard, and its attainment of quality goals.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage will be between 0% and 150%. The payable portion of the pool is then separated into an Assigned Bonus Pool for each Business Group, Region and Unit, based on their performance as to their respective Scorecards.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Management System then allocates the Assigned Bonus Pools among the managers, who evaluate the performance of the participants under their management and determine, for each participant, the percentage (between 0% and 150%) of the participant&#8217;s Target Annual Bonus that will be the participant&#8217;s Bonus Award for the Performance Year. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan's purpose is to align the Company's interests and your interests as a Plan participant by providing incentive compensation for the achievement of Company and individual performance objectives.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The capitalized words and terms that are used throughout the Plan are defined in the Glossary in Article IX.</font></div><div style="padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">II.&#160;&#160;&#160;&#160;Eligibility and Participation</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You are eligible to participate in the Plan for a Performance Year if you satisfy all of the following eligibility criteria&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">You are either a Regular Employee or an Eligible International Employee&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">You are not eligible for commissions under any sales compensation plan of the Company (unless the written terms of the plan or program expressly permit participation in both that plan or program and the Plan)&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">You are not eligible to participate in any other incentive plan or program of the Company (unless the written terms of that plan or program expressly permit participation in both that plan or program and the Plan)&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">You complete at least two full months of Eligible Service during the Performance Year.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For exempt employees and eligible international employees, if you are eligible to participate in the Plan for only part of the Performance Year (for example, because you change positions or business units during the Performance Year), then you may participate in the Plan on a prorated basis for the Performance Year, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided that</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> you complete at least two full months of Eligible Service during the Performance Year.  If you are eligible for prorated participation, the Bonus Award, if any, otherwise payable to you for the Performance Year will be prorated based on your percentage of time in an eligible position during the Performance Year.  This paragraph does not apply to non-exempt employees.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">III.&#160;&#160;&#160;&#160;Target Annual Bonus</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div><img alt="logo2021compensationplans.jpg" src="logo2021compensationplans.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:169px"></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><font style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><br></font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2022 Boston Scientific Annual Bonus Plan </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Version&#58; November 2021</font></div></td></tr></table></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exempt employees and eligible international employees&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For each Performance Year in which you are eligible to participate, you will be assigned a Target Annual Bonus, which will be a specified percentage of your annual base salary, determined based on your position.  The Bonus Award, if any, that you ultimately receive for the Performance Year will be a percentage of your </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Target Annual Bonus, determined pursuant to Article IV. The Aggregate Bonus Pool for a Performance Year will be the sum of the Target Annual Bonuses of all employees who are eligible to participate in the Plan for the Performance Year. All Bonus Awards will be based on your salary and incentive target as of December 31 of the Performance Year.  </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-exempt employees&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For each Performance Year in which you are eligible to participate, you will be assigned a Target Annual Bonus, which will be a specified percentage of your total annual earnings including overtime earnings, determined based on your position.  The Bonus Award, if any, that you ultimately receive for the Performance Year will be a percentage of your Target Annual Bonus, determined pursuant to Article IV. The Aggregate Bonus Pool for a Performance Year will be the sum of the Target Annual Bonuses of all employees who are eligible to participate in the Plan for the Performance Year. All Bonus Awards will be based on your salary and incentive target as of December 31 of the Performance Year.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">IV.&#160;&#160;&#160;&#160;Steps For Determining Bonus Awards</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bonus Awards for a Performance Year will be determined pursuant to the following steps&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Step One&#58; Establish performance goals, quality goals and the Corporate Performance Scale</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or before March 15 of a Performance Year, the Committee will establish performance goals for each of the Plan's Performance Metrics and quality goals for the Performance Year.  The Performance Metrics are Global Sales, Adjusted Earnings Per Share and a Human Capital Scorecard.  The Committee will also approve the Corporate Performance Scale for the Performance Year, which will be set forth in a separate schedule.  </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Step Two&#58;  Measure achievement and determine Total Annual Bonus </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the end of the Performance Year, the Committee will evaluate the Company's financial performance results for the Performance Year and determine the extent to which the performance goals were attained.  The Committee will adopt a written resolution as to the extent of the attainment of the performance goals with respect to each of the Performance Metrics.  Based on the extent to which the performance goals were attained, the Chief Executive Officer will make a recommendation to the Committee, consistent with the Corporate Performance Scale, as to the Applicable Percentage of the Aggregate Bonus Pool to be paid by the Company as the Total Annual Bonus for the Performance Year.  Taking into account the Chief Executive Officer's recommendation and any other factors that the Committee, in its discretion, deems appropriate, the Committee will approve an Applicable Percentage for the Performance Year, which must be consistent with the Corporate Performance Scale.  The Committee retains the right to reduce the Total Annual Bonus for the Performance Year based on the Committee's assessment of Quality.      </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Step Three&#58; Allocate the Total Annual Bonus</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chief Executive Officer will make a recommendation to the Committee as to how the Total Annual Bonus for the Performance Year should be allocated among the Business Groups and Regions, based on their overall and relative performance against their respective applicable Scorecards for the Performance Year.  Taking into account the Chief Executive Officer's recommendation and any other factors that the Committee, in its discretion, deems appropriate, the Committee will approve an allocation of the Total Annual Bonus among the Business Groups </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div><img alt="logo2021compensationplans.jpg" src="logo2021compensationplans.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:169px"></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><font style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><br></font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2022 Boston Scientific Annual Bonus Plan </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Version&#58; November 2021</font></div></td></tr></table></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Regions for the Performance Year.  The portion of the Total Annual Bonus allocated to a Business Group or Region (its Assigned Bonus Pool) will be a percentage of the total Target Annual Bonuses of all its employees who participate in the Plan for the Performance Year.  If a Business Group or Region has Units, the leader of the Business Group or Region will divide the Assigned Bonus Pool among the Units, based on their overall and relative performance against each Unit's applicable Scorecard for the Performance Year, so that each Unit will then have its </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">own Assigned Bonus Pool.  A Business Group or Region that does not have Units (for example, Corporate) will have a single Assigned Bonus Pool.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Step Four&#58; Determine participants' individual Bonus Awards</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the Assigned Bonus Pool is determined for each Business Group, Region, or Unit, the amount of the Assigned Bonus Pool will be entered into the Compensation Management System, which allocates a portion of the Assigned Bonus Pool to each manager of Plan participants.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each manager will evaluate the performance of each participant under his or her management and enter into the Compensation Management System a rating percentage, from 0% to 150%, for each evaluated participant.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rating percentage that your manager assigns to you will, in turn, determine the percentage of your Target Annual Bonus that will be your Bonus Award for the Performance Year.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If participants leave the Company before the Payment Date and, as a result, do not earn their Bonus Awards for the Performance Year, their Bonus Awards will be reallocated by the Chief Executive Officer, in his or her discretion, to other participants who are employed on the Payment Date and will become part of the Bonus Awards paid to those other participants.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As provided in Article V, all Bonus Awards for a Performance Year (including those reallocated pursuant to the previous sentence) will be paid to eligible participants no later than March 15 of the following year.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">V.&#160;&#160;&#160;&#160;Payment Conditions</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Date and Form of Payment.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Bonus Awards in the United States will be made by March 15 of the year following the Performance Year for which the Bonus Awards are made. Bonus Awards outside the United States will be processed as soon as administratively possible in each region following the end of the Performance Year and after the Committee has adopted its written resolution as to the attainment of performance goals pursuant to Article IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Your Bonus Award, if any, will be paid in a single lump sum payment.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Required Employment on the Payment Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Except as otherwise expressly provided in this Article V, to be eligible to receive payment of any Bonus Award, you must be employed by the Company on the Payment Date for that Bonus Award.  In other words, except as expressly provided in this Article V, if you cease employment with Boston Scientific Corporation and all of its Affiliates before the Payment Date, you will not be eligible to receive any Bonus Award that would otherwise have been payable to you if you had been a Company employee on that date.  Conversely, if you are an employee of the Company on the Payment Date, you will be entitled to your Bonus Award, if any, even if you are not actively performing duties on that date.  For example, if you are not required to report to work during a notification period applicable under a Company severance or separation plan, but you are still a Company employee during that period, and the Payment Date occurs during your notification period, you will remain eligible to receive your Bonus Award.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exception Under Written Company Plan or Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If you are specifically exempted, under a written Company plan or agreement, from the requirement to be employed on the Payment Date, </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div><img alt="logo2021compensationplans.jpg" src="logo2021compensationplans.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:169px"></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><font style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><br></font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2022 Boston Scientific Annual Bonus Plan </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Version&#58; November 2021</font></div></td></tr></table></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">you may remain eligible for payment of your Bonus Award, depending on the terms of the applicable written plan or agreement.  In such cases, the terms of such written plan or agreement will govern in all respects.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Layoff</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Also notwithstanding any other provision of the Plan, if you are a participant and your employment ceases prior to the Payment Date by reason of Layoff, you may be eligible for payment of part or all of your Bonus Award, depending on the terms and conditions of the applicable severance pay plan, if any, for the country in which you are employed at the time of layoff. In the event that there is no country-specific severance plan for the country in which you are employed at the time of your Layoff, applicable law will apply.  In the event a previously eligible participant is re-hired within the Performance Year after a layoff and meets the eligibility </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">criteria, if they were paid out a pro-rated bonus at the time of severance, then the payout period would not be bridged. If the re-hire had not received pro-rated bonus at the time of severance, then the payout period would be bridged, and they would receive a pro-rated bonus for the Performance Year. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Also notwithstanding any other provision of the Plan, if you are a participant on a paid leave of absence, you are bonus eligible as long as you meet performance expectations during the Performance Year. Your bonus award will be made on the payment date within the applicable country. If you are a participant on an unpaid leave of absence, your bonus award, if any, will be pro-rated if the unpaid leave is longer than a continuous six (6) months in duration during the Performance Year. Country specific regulations regarding leaves of absence and bonus eligibility supersede this Plan document.     </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Also notwithstanding any other provision of the Plan, if you are an exempt employee or an eligible international employee participant and your employment ceases prior to the Payment Date for a Bonus Award but after September 30 of the Performance Year to which the Bonus Award pertains, and you had at least nine months of Eligible Service in the Performance Year, you will be entitled to a prorated portion of the Bonus Award, if any, that would otherwise be paid you if, as of the date of your cessation of employment, (1) you had attained age 55, (2) you had accrued at least five years of service with the Company and (3) the sum of your age and years of service as of your date of cessation of employment equals or exceeds 65.  In such a case, proration will be based on the percentage of time in the Performance Year during which you were employed and eligible to participate in the Plan.  The prorated Bonus Award, if any, will be paid on the Payment Date.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For non-exempt employees, if you are a retiree, you will be entitled to your Bonus Award if your employment ceases prior to the Payment Date for a Bonus Award but after September 30 of the Performance Year to which the Bonus Award pertains, and you had at least nine months of Eligible Service in the Performance Year.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  For exempt employees and eligible international employees, if your employment ceases prior to the Payment Date by reason of your death, but you otherwise met all eligibility criteria specified in Article II, your estate may receive a prorated portion of the Bonus Award, if any, that would have been paid had you lived to the Payment Date.  In such a case, proration will be based on the percentage of time in the Performance Year during which you were employed and eligible to participate in the Plan.  The prorated Bonus Award, if any, will be paid on the Payment Date. </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For non-exempt employees, if your employment ceases prior to the Payment Date by reason of your death, but you otherwise met all eligibility criteria specified in Article II, your estate will receive your Bonus Award, if any, that would have been paid had you lived to the Payment Date.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustment for Changes in Standard Hours</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Also notwithstanding any other provision of the Plan, if you are an exempt employee or eligible international employee participant and have a change </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div><img alt="logo2021compensationplans.jpg" src="logo2021compensationplans.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:169px"></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><font style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><br></font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2022 Boston Scientific Annual Bonus Plan </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Version&#58; November 2021</font></div></td></tr></table></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in standard hours (part-time to full-time, full-time to part-time) during a Performance Year, your Bonus Award, if any, for the Performance Year will be calculated as follows&#58;  Target Annual Bonus percentage multiplied by the average annualized base salary for each period of employment at a specific salary divided by the percentage of the year during which that salary was earned.  For example, if your Target Annual Bonus percentage is 10% and you worked full-time for six (6) months at an annual base pay of 100,000 and moved to a part-time arrangement for the remaining (6) months at an annual base pay of 50,000, your bonus award, if any, would be 7,500.  &#91;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">0.10 x (100,000 x 0.50) &#61; 5,000&#93; and &#91;0.10 x (50,000 x 0.50) &#61; 2,500&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This paragraph does not apply to non-exempt employee participants.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Guarantee of a Bonus Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Nothing in this Plan guarantees that any Bonus Award will be made to any individual.  Receipt of a Bonus Award in one year does not guarantee eligibility in any future year.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">VI.&#160;&#160;&#160;&#160;Incentive Compensation Recoupment Policy</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General Recoupment Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent permitted by governing law, the Board, in its discretion, may seek reimbursement of a Bonus Award paid to you if you are a Current Executive Officer or Former Executive Officer and you, in the judgment of the Board, commit misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in your capacity as Executive Officer.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in such case&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-22.99pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">if you are a Current Executive Officer, the Board may seek reimbursement of all or a portion of the Bonus Award paid to you during the one-year period preceding the date on which such misconduct or dereliction of duty was discovered by the Company, or</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if you are a Former Executive Officer, the Board may seek reimbursement of all or a portion of the Bonus Award paid to you during the one-year period preceding the last date on which you were a Current Executive Officer. </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Restatement of Financial Results</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  To the extent permitted by governing law, if you are an Executive Officer, the Board will seek reimbursement of a Bonus Award paid to you in the event of a restatement of the Company's financial results that reduced a previously granted Bonus Award's size or payment.  In that event, the Board will seek to recover the amount of the Bonus Award paid to you that exceeded the amount that would have been paid based on the restated financial results.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Provisions Required by Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If the Company subsequently determines that it is required by law to apply a &#34;clawback&#34; or alternate recoupment provision to a Bonus Award, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to the Bonus Award, as applicable, as if it had been included on the date the Plan was established and the Company shall notify you of such additional provision.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">VII.&#160;&#160;&#160;&#160;Termination, Suspension or Modification and Interpretation of the Plan</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board may terminate, suspend or modify (and if suspended, may reinstate with or without modification) all or part of the Plan at any time, with or without notice to participants.  The Committee has sole authority over administration and interpretation of the Plan, and the Committee retains its right to exercise discretion as it sees fit. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee reserves the exclusive right to determine eligibility to participate in this Plan and to interpret all applicable terms and conditions, including eligibility criteria, performance objectives </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div><img alt="logo2021compensationplans.jpg" src="logo2021compensationplans.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:169px"></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><font style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><br></font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2022 Boston Scientific Annual Bonus Plan </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Version&#58; November 2021</font></div></td></tr></table></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and payment conditions, for the Company's executive officers.  The Committee delegates to the Company&#8217;s highest human resources officer the authority to administer, and determine eligibility to participate in, the Plan and interpret all applicable terms and conditions for employees who are not executive officers of the Company.  The determinations and interpretations of the Committee and its delegates will be conclusive.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Bonus Awards are paid from the Company's general assets.  No trust, account or other separate collection of amounts will be established for the payment of Bonus Awards under the Plan.  Bonus Awards are unfunded obligations of the Company, so if and when a Bonus Award becomes due, a participant's rights to payment are no greater than the rights of a general unsecured creditor.  </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">VIII.&#160;&#160;&#160;&#160;Other</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This document sets forth the terms of the Plan and is not intended to be a contract or employment agreement between you or any other participant and the Company.  As applicable, it is understood that both you and the Company have the right to terminate your employment with the Company at any time, with or without cause and with or without notice, in acknowledgement of the fact that your employment relationship with the Company is &#8220;at will.&#8221;</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">IX.&#160;&#160;&#160;&#160;Glossary</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in the Plan, the following words and terms, when capitalized, have the following meanings&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjusted Earnings Per Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, with respect to a Performance Year, Adjusted Net Income (loss) divided by weighted average shares outstanding for the Performance Year (determined in accordance with generally accepted accounting principles).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjusted Net Income (loss</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) equals the Company's GAAP Net Income (loss)  excluding certain charges (credits) from GAAP net income, including, but not limited to, amortization expense, goodwill and intangible asset impairment charges, acquisition- and divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), certain investment impairment losses (gains), EU Medical Device Regulation implementation charges, pension termination charges, and discrete tax items. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means any corporation, trust, partnership, or any other entity that is considered to be a single employer with Boston Scientific Corporation under Code sections 414(b), (c), (m), or (o), such as a wholly-owned (or at least 80%-owned) subsidiary of Boston Scientific Corporation.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Aggregate Bonus Pool</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, with respect to a Performance Year, the sum of the Target Annual Bonuses of all employees who are eligible to participate in the Plan for the Performance Year.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Percentage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, with respect to a Performance Year, a percentage, determined by the Committee in accordance with the Corporate Performance Scale, which is between 0% and no more than 150%.  The Applicable Percentage is used to determine the portion of the Aggregate Bonus Pool that the Company will pay out as the Total Annual Bonus for the Performance Year.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assigned Bonus Pool</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, with respect to a Business Group, Region, or Unit for a Performance Year, the portion of the Total Annual Bonus assigned to the Business Group, Region, or Unit to be paid as Bonus Awards for the Performance Year to eligible participants who worked for the Business Group, Region, or Unit during the Performance Year.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div><img alt="logo2021compensationplans.jpg" src="logo2021compensationplans.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:169px"></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><font style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><br></font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2022 Boston Scientific Annual Bonus Plan </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Version&#58; November 2021</font></div></td></tr></table></div></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the Board of Directors of Boston Scientific Corporation.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bonus Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, with respect to a participant for a Performance Year, the annual incentive bonus, if any, payable to the participant for the Performance Year, subject to the terms and conditions of the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Business Group</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means a functional or product-based area of the Company's business, as designated by the Chief Executive Officer from time to time. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Chief Executive Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the Chief Executive Officer of Boston Scientific Corporation.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Code means the Internal Revenue Code of 1986, as amended, and its interpretive rules and regulations.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the Executive Compensation and Human Resources Committee of the Board.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company means Boston Scientific Corporation and its Affiliates.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation Management System</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the software tool used by the Company for various compensation management purposes.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Performance Scale</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, with respect to a Performance Year, the schedule used to determine, based on the extent of attainment of the performance goals for the Performance Year, the Applicable Percentage of the Aggregate Bonus Pool to be paid as the Total Annual Bonus for the Performance Year.  The Corporate Performance Scale must provide that the Applicable Percentage for a Performance Year cannot be less than 50%.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Current Executive Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means any individual currently designated as an &#8220;officer&#8221; by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Eligible International Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means an international, international operations, or expatriate employee of the Company working in a position designated by the Company as eligible to participate in the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Eligible Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means periods in which you are considered, under the rules and procedures of the Company, to be in active service as a Regular Employee or Eligible International Employee (including, but not limited to, time away from work for approved vacation, recognized holidays, and FMLA leave).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Executive Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means any Current Executive Officer or Former Executive Officer.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exempt Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means an employee of the Company who is on the Company's United States payroll and (1) classified by the Company as a regular full-time or regular part-time Employee&#59; (2) performs a job that the Company has determined to be exempt from the minimum wage and overtime requirements of the Fair Labor Standards Act of 1938, as amended (FLSA)&#59; and (3) is </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> any of the following&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">classified by the Company as an intern, summer student, co-op employee, or similar short-term employee&#59; or</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">classified by the Company as a consultant, temporary or defined-term employee (such as temporary fellowship program employees), or similar category of limited-term employment, regardless of their work schedule or number of hours worked.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div><img alt="logo2021compensationplans.jpg" src="logo2021compensationplans.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:169px"></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><font style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><br></font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2022 Boston Scientific Annual Bonus Plan </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Version&#58; November 2021</font></div></td></tr></table></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Former Executive Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means any individual previously (but not currently) designated as an &#8220;officer&#8221; by the Board for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Global Sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for purposes of the Annual Bonus Plan measures sales excluding the impact of foreign currency fluctuations and excluding acquisitions and divestitures not included in the annual operating plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Human Capital Scorecard means</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with respect to a Performance Year, performance against global gender and US (inclusive of Puerto Rico) multicultural goals that are aligned to 3UP 2023 goals, leadership goals, and performance against annual environmental goals that are aligned with the Company&#8217;s environmental strat plan goals.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Layoff</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means a layoff or similar involuntary termination from employment that renders you eligible for severance pay under a Company severance plan or applicable law.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Exempt Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means an employee of the Company who is on the Company's United States payroll and (1) classified by the Company as a regular full-time or regular part-time Employee&#59; and (2) performs a job that the Company has determined to be non-exempt from the minimum wage and overtime requirements of the Fair Labor Standards Act of 1938, as amended (FLSA).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, with respect to a Performance Year, the date on which Bonus Awards for the Performance Year are paid to participants, which will be no later than March 15 of the following year.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance Metrics</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means Global Sales, Adjusted Earnings Per Share, and Human Capital Scorecard.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance Year</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the 12-month period beginning on January 1 and ending on the following December 31. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the Boston Scientific Annual Bonus Plan, which is set forth in this document, as it may be amended from time to time.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Quality Assessment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the process undertaken by the Committee following the end of each Performance Year, to evaluate the Company's progress made toward achievement of its quality objectives and the performance of the Company-wide quality system.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Region</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means a geographic region, as designated by the Chief Executive Officer from time to time, comprising a portion of the Company's international business.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Regular Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means an employee of the Company who is on the Company's United States payroll and is considered an Exempt Employee or Non-Exempt Employee. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Scorecard</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, with respect to a Performance Year, the tool used to establish performance measures and objectives with respect to a Business Group, Region, or Unit for the Performance Year. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Target Annual Bonus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has the meaning given to that term in Article III.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Total Annual Bonus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents, with respect to a Performance Year, the total dollars to be paid out by the Company to all participating employees as Bonus Awards for the Performance Year.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div><img alt="logo2021compensationplans.jpg" src="logo2021compensationplans.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:169px"></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><font style="font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><br></font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2022 Boston Scientific Annual Bonus Plan </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Performance Period January 1 - December 31</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Version&#58; November 2021</font></div></td></tr></table></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Unit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means a business unit of Business Group or Region, such as a plant or division (for a Business Group) or a country or group of countries (for a Region)&#59; the Units of a Business Group or Region may change from time to time.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102bostonscientific.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i68b53674e74b4425bdb339ce0eff8110_1"></div><div style="min-height:72pt;width:100%"><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:261.00pt"><tr><td style="width:1.0pt"></td><td style="width:259.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)<br>Total Shareholder Return Performance Share Program<br>(&#8220;TSR Program&#8221;)<br>Performance Period January 1, 2022 - December 31, 2024</font></td></tr></table></div><div style="padding-left:216pt;text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:29.34pt">Purpose of the TSR Program</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the TSR Program is to align Boston Scientific&#8217;s executive compensation program with the interests of shareholders and to reinforce the concept of pay for performance by comparing the Total Shareholder Return (&#8220;TSR&#8221;) of shares of Boston Scientific Common Stock (the &#8220;Common Stock&#8221;) to the TSR of companies included in the S&#38;P 500 Healthcare Index over a three-year period beginning on January 1, 2022.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TSR Program entails the grant of Restricted Stock Units, and the program shall be administered, under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;2011 LTIP&#8221;).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terms not defined in this TSR Program document but defined in the 2011 LTIP shall have the same meaning as in the 2011 LTIP. For Covered Employees, the TSR Program is established under section 4.a.(8) of the 2011 LTIP.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">II. &#160;&#160;&#160;&#160;Eligible Participants</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TSR Program covers members of the Executive Committee on the date that awards are granted under the TSR Program as determined and in the amounts established by the Executive Compensation and Human Resources Committee of the Board of Directors (the &#8220;Committee&#8221;).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee may review TSR Program eligibility criteria for participants in the TSR Program from time to time and may revise such criteria at any time, even within a TSR Program year, with or without notice and within its sole discretion.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">III.      Performance Share Units </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restricted Stock Units awarded under the TSR Program (the &#8220;Performance Share Units&#8221;) shall vest only upon satisfaction of both the performance criteria described in this Section III and the payment eligibility criteria described in Section VII.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable performance criteria are based on the TSR of the Common Stock relative to the TSR of companies in the S&#38;P 500 Healthcare Index.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TSR for Boston Scientific and all other companies in the S&#38;P 500 Healthcare Index will be measured over a three-year period beginning January 1, 2022 and ending on December 31, 2024 (the &#8220;Performance Period&#8221;). </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Performance Share Units as to which the performance criteria under this program shall be determined to have been satisfied will be in a range of 0% to 200% of the target number of Performance Share Units awarded to the participant as follows&#58; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.666%"><tr><td style="width:1.0%"></td><td style="width:48.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">TSR Performance<br>Percentile Rank</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Performance Share Units as a Percent of Target</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">80th Percentile or above</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">200%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">50th Percentile</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">100%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">30th Percentile</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Below 30</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Percentile</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0%</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:261.00pt"><tr><td style="width:1.0pt"></td><td style="width:259.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)<br>Total Shareholder Return Performance Share Program<br>(&#8220;TSR Program&#8221;)<br>Performance Period January 1, 2022 - December 31, 2024</font></td></tr></table></div><div style="padding-left:216pt;text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the minimum level of performance is achieved, the number of Performance Share Units will be calculated linearly between each set of data points. </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the end of the Performance Period, the Committee shall determine the number of Performance Share Units as to which the performance criteria of this program have been satisfied, which determination shall be final and binding. Shares of Common Stock will be delivered or otherwise made available to the participant no later than March 15, 2025 in settlement of the Performance Share Units as to which the performance criteria of this program have been satisfied if and to the extent the payment eligibility criteria of Section VII below are also satisfied.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any Performance Share Units as to which the performance criteria of this Section III have not been satisfied will be forfeited in their entirety.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IV.&#160;&#160;&#160;&#160;Calculation of Total Shareholder Return and Definitions</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TSR for Boston Scientific and each other company in the S&#38;P 500 Healthcare Index shall include any cash dividends paid during the Performance Period and shall be determined as follows&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Shareholder Return for the Performance Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#61; </font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Change in Stock Price + Dividends Paid) &#47; Beginning Stock Price</font></div><div style="text-indent:72pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Beginning Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the daily average closing price as quoted on the New York Stock Exchange or the NASDAQ Global Select Market, as applicable, of one (1) share of common stock for the two calendar months </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">prior</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the beginning of the Performance Period. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the difference between the Beginning Stock Price and the Ending Stock Price.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends Paid</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the total of all cash dividends paid on one (1) share of stock during the Performance Period.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ending Stock Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the daily average closing price as quoted on the New York Stock Exchange or the NASDAQ Global Select Market, as applicable, of one (1) share of common stock for the last two calendar months of the Performance Period.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Example&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Beginning Stock Price for a company was $25.00 per share, and the company paid $2.50 in dividends over the Performance Period, and the Ending Stock Price was $30.00 per share (thereby making the Change in Stock Price $5.00 ($30.00 minus $25.00)), then the TSR for that company would be thirty percent (30%).  The calculation is as follows&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.30</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#61; ($5.00 + $2.50) &#47; $25.00</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">V.&#160;&#160;&#160;&#160;Calculation of Percentile Performance</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the calculation of the TSR for the Performance Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Boston Scientific and each of the other companies in the S&#38;P 500 Healthcare Index, Boston Scientific and the other companies in the S&#38;P 500 Healthcare Index will be ranked, in order of maximum to minimum, according to their respective TSR for the Performance Period.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:261.00pt"><tr><td style="width:1.0pt"></td><td style="width:259.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)<br>Total Shareholder Return Performance Share Program<br>(&#8220;TSR Program&#8221;)<br>Performance Period January 1, 2022 - December 31, 2024</font></td></tr></table></div><div style="padding-left:216pt;text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After this ranking, the percentile performance of Boston Scientific as compared to the other companies in the S&#38;P 500 Healthcare Index shall be determined by the following formula&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><img alt="percentileperformancecalcu.jpg" src="percentileperformancecalcu.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:139px"></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;P&#8221; represents the percentile performance which will be rounded, if necessary, to the nearest whole percentile by application of standard scientific rounding conventions. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;N&#8221; represents the number of companies in the S&#38;P 500 Healthcare Index, including Boston Scientific.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;R&#8221; represents Boston Scientific&#8217;s ranking versus the other companies in the S&#38;P 500 Healthcare Index. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Example&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If Boston Scientific ranked 10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> out of 54 companies, the performance (&#8220;P&#8221;) therefore will be in the 83</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> percentile.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This calculation is as follows&#58;     </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">0.83</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#61; 1 &#8211; (10 &#8211; 1) &#47; (54 &#8211; 1)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">VI. &#160;&#160;&#160;&#160;S&#38;P 500 Healthcare Index </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The companies currently included in the S&#38;P 500 Healthcare Index can be found in Appendix A attached hereto.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Only companies in the S&#38;P 500 Healthcare Index for an entire Performance Period will be used to determine the TSR percentile rank. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If two companies in the S&#38;P 500 Healthcare Index merge, the surviving company shall remain in the S&#38;P 500 Healthcare Index.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If a company in the S&#38;P 500 Healthcare Index merges with, or is acquired by, a company that is not in the S&#38;P 500 Healthcare Index, and the company in the S&#38;P 500 Healthcare Index is the surviving company, then the surviving company shall be included in the S&#38;P 500 Healthcare Index.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If a company in the S&#38;P 500 Healthcare Index merges with, or is acquired by, a company that is not in the S&#38;P 500 Healthcare Index, and the company in the S&#38;P 500 Healthcare Index is not the surviving company or the surviving company is no longer publicly traded, then the surviving company shall not be included in the S&#38;P 500 Healthcare Index.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Notwithstanding the foregoing, if a company in the S&#38;P 500 Healthcare Index ceases to be listed in the Healthcare Sector under the Standard &#38; Poor&#8217;s Global Industry Classification Standard (GICS) at any time during the Performance Period (including after a merger, acquisition or other business transaction described above), then it shall not be included in the S&#38;P 500 Healthcare Index. </font></div><div style="padding-left:36pt;text-indent:4.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">VII.&#160;&#160;&#160;&#160;Payment Eligibility Criteria</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth below with respect to a Change in Control, no Performance Share Units shall vest prior to the end of the Performance Period (December 31, 2024). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:261.00pt"><tr><td style="width:1.0pt"></td><td style="width:259.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)<br>Total Shareholder Return Performance Share Program<br>(&#8220;TSR Program&#8221;)<br>Performance Period January 1, 2022 - December 31, 2024</font></td></tr></table></div><div style="padding-left:216pt;text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a participant&#8217;s employment with Boston Scientific and its Affiliates (the &#8220;Company&#8221;) terminates before January 1, 2023, all of his or her Performance Share Units shall be forfeited in their entirety except as set forth below with respect to a termination of employment due to death or Disability.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a participant&#8217;s employment with the Company terminates after December 31, 2022 but before the end of the Performance Period, all of his or her Performance Share Units shall be forfeited, except in connection with Retirement, death, Disability or upon a Change of Control as outlined below.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants on military, sick or other bona fide leave of absence on December 31, 2024 will not be deemed to have terminated employment with the Company if such absence does not exceed 180 days or, if longer, the period the participant retains the right by statute or by contract to return to employment with the Company. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of any separate Change in Control or similar agreement to which a participant is bound, if there is a Change in Control after December 31, 2022 but before the end of the Performance Period, shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this program have been satisfied using the last day of the month preceding the date on which the Change in Control is consummated as the ending date of the Performance Period in lieu of December 31, 2024, as determined by the Committee immediately prior to the consummation of the Change in Control.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such issuance shall occur within 70 days of the effective date of the termination or Change in Control, on a prorated basis. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares to be issued on a prorated basis shall be determined as follows&#58; (# Performance Share Units achieved pursuant to the table in Section III * ((# of full and partial months during the Performance Period, rounded up to the nearest whole month&#47;36)).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of prorated shares to be issued to the participant, if any, will be approved by the Committee at its next regular meeting.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event a Change in Control occurs prior to January 1, 2021, the Performance Share Units will be forfeited in their entirety.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a participant&#8217;s employment with the Company terminates due to Retirement after December 31, 2022 but before the end of the Performance Period, shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this program have been satisfied at the end of the Performance Period, but no later than March 15, 2025, on a prorated basis using the effective date of the participant&#8217;s termination of employment. The number of shares to be issued on a prorated basis shall be determined as follows&#58; (# Performance Share Units achieved pursuant to the table in Section III * ((# of full and partial months worked during the Performance Period, rounded up to nearest whole month) &#47; 36)).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of prorated shares to be issued to the participant, if any, will be approved by the Committee at its next regular meeting. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a participant&#8217;s employment with the Company terminates due to death or Disability before the end of the Performance Period, all of his or her Performance Share Units shall accelerate vesting and shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this program have been satisfied at the end of the Performance Period, but no later than March 15, 2025. The number of shares to be issued to the participant, if any, will be approved by the Committee at its next regular meeting. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:261.00pt"><tr><td style="width:1.0pt"></td><td style="width:259.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)<br>Total Shareholder Return Performance Share Program<br>(&#8220;TSR Program&#8221;)<br>Performance Period January 1, 2022 - December 31, 2024</font></td></tr></table></div><div style="padding-left:216pt;text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">VIII. &#160;&#160;&#160;&#160;Termination, Suspension or Modification and Interpretation of the TSR Program</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee has sole authority over administration and interpretation of the TSR Program and retains its right to exercise discretion as it sees fit, except that, with respect to Covered Employees, the Committee shall have no discretion to increase the number of shares of Common Stock in which a participant may vest above the amount described in Section III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee may terminate, suspend or modify and if suspended, may reinstate with or without modification all or part of the TSR Program at any time, with or without notice to the participant.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee reserves the exclusive right to determine eligibility to participate in this TSR Program and to interpret all applicable terms and conditions, including eligibility criteria.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">IX.&#160;&#160;&#160;&#160;Recoupment Policy</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">General Recoupment Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the extent permitted by governing law, the Board, in its discretion, may seek Recovery of Performance Share Units granted to a Current Executive Officer or Former Executive Officer if, in the judgment of the Board, such Executive Officer commits misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in capacity as Executive Officer.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following terms shall have the meaning set forth below&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">            </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Current Executive Officer&#34; means any individual currently designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 of the Securities Exchange Act of 1934, as amended.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">            </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Executive Officer&#34; means any Current Executive Officer or Former Executive Officer.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">            </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Former Executive Officer&#34; means any individual previously (but not currently) designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 of the Securities Exchange Act of 1934, as amended.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Recovery&#34; means the forfeiture or cancellation of unvested Performance Share Units.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Provisions Required by Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company subsequently determines that it is required by law to apply a &#34;clawback&#34; or alternate recoupment provision to outstanding Performance Share Units, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to the Performance Share Units, as applicable, as if it had been included on the date the Performance Share Units were granted and the Company shall notify the participant of such additional provision.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">X. &#160;&#160;&#160;&#160;Other</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:261.00pt"><tr><td style="width:1.0pt"></td><td style="width:259.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)<br>Total Shareholder Return Performance Share Program<br>(&#8220;TSR Program&#8221;)<br>Performance Period January 1, 2022 - December 31, 2024</font></td></tr></table></div><div style="padding-left:216pt;text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This document sets forth the terms of the TSR Program and is not intended to be a contract or employment agreement between the participant and the Company.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As applicable, it is understood that both the participant and the Company have the right to terminate the participant&#8217;s employment with the Company at any time, with or without cause and with or without notice, in acknowledgement of the fact that their employment relationship is &#8220;at will.&#8221; </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent section 409A of the Internal Revenue Code (&#8220;Code&#8221;) applies to any award under this TSR Program, the award shall be interpreted in a manner consistent with Code section 409A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where section 409A applies, in the case of any payment made on termination of employment, a termination of employment shall not be deemed to have occurred unless such termination is also a &#8220;separation from service&#8221; within the meaning of Code section 409A and, for purposes of any such provision, references to a &#8220;termination,&#8221; &#8220;termination of employment,&#8221; or like terms shall mean &#8220;separation from service.&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where section 409A applies, in the case of a payment made upon a Change in Control, a Change in Control shall not be deemed to have occurred unless there is a change in the ownership or effective control of Boston Scientific, or in the ownership of a substantial portion of the assets of Boston Scientific, as defined in Code section 409A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where required by section 409A in the case of a specified employee (as determined under Code section 409A), payments on termination shall be made on the first business day of the seventh month following termination.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:261.00pt"><tr><td style="width:1.0pt"></td><td style="width:259.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)<br>Total Shareholder Return Performance Share Program<br>(&#8220;TSR Program&#8221;)<br>Performance Period January 1, 2022 - December 31, 2024</font></td></tr></table></div><div style="padding-left:216pt;text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:115%;text-decoration:underline">Appendix A</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Annual Executive LTIP Program</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">S&#38;P 500 Healthcare Index &#8211; 64 Companies</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company Name</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Agilent Technologies, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Henry Schein, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AbbVie Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Humana Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AmerisourceBergen Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IDEXX Laboratories, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Abbott Laboratories</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Illumina, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CVS Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Incyte Corporation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bio-Rad Laboratories</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intuitive Surgical, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Align Technology, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &#38; Johnson</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bio-Techne Cp</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Laboratory Corporation of America Holdings</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amgen Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Eli Lilly and Company</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Anthem, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">McKesson Corporation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Abiomed Inc</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medtronic plc</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Baxter International Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Merck &#38; Co., Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Becton, Dickinson and Company</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mettler-Toledo International Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moderna Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bristol-Myers Squibb Company</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Steris Corp</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Boston Scientific Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pfizer Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cardinal Health, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PerkinElmer, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Catalent Inc</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Organon &#38; Co.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cerner Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IQVIA Holdings, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cigna Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regeneron Pharmaceuticals, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Centene Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ResMed Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cooper Companies</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stryker Corporation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quest Diagnostics Incorporated</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thermo Fisher Scientific Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Danaher Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Universal Health Services, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">DaVita Healthcare Partners Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">UnitedHealth Group Incorporated</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dexcom</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Viatris Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">DENTSPLY SIRONA Inc</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vertex Pharmaceuticals Incorporated</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Edwards Lifesciences Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Waters Corporation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gilead Sciences, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Teleflex Inc</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HCA Healthcare, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Zimmer Biomet Holdings, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Hologic, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Zoetis Inc</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles River Laboratories Intl.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">West Pharmaceutical Services</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exhibit103bostonscientific.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4883ec38d3494dfabbf47dc7bfdda2e4_1"></div><div style="min-height:72pt;width:100%"><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:249.75pt"><tr><td style="width:1.0pt"></td><td style="width:247.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)<br>Free Cash Flow Performance Share Program<br>(&#8220;FCF Program&#8221;)<br>Performance Period January 1, 2022 - December 31, 2022</font></td></tr></table></div><div style="padding-left:216pt;text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">I.&#160;&#160;&#160;&#160;Purpose of the FCF Program</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the FCF Program is to align Boston Scientific&#8217;s executive compensation program with the interests of shareholders and to reinforce the concept of pay for performance by providing incentives for the achievement of key business performance objectives which are critical to the success of Boston Scientific.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCF Program entails the grant of Restricted Stock Units, and the program shall be administered, under the Boston Scientific Corporation Amended and Restated 2011 Long-Term Incentive Plan (the &#8220;2011 LTIP&#8221;).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terms not explicitly defined in this FCF Program document but defined in the 2011 LTIP shall have the same meaning as in the 2011 LTIP. For Covered Employees, the FCF Program is established under section 4.a.(8) of the 2011 LTIP.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">II.&#160;&#160;&#160;&#160;Eligible Participants</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCF Program covers members of the Executive Committee on the date that awards are granted under the FCF Program as determined and in the amounts established by the Executive Compensation and Human Resources Committee of the Board of Directors (the &#8220;Committee&#8221;).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee may review FCF Program eligibility criteria for participants in the FCF Program from time to time and may revise such criteria at any time, even within a FCF Program year, with or without notice and within its sole discretion.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">III.&#160;&#160;&#160;&#160;Performance Share Units </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restricted Stock Units awarded under the FCF Program (the &#8220;Performance Share Units&#8221;) shall vest only upon satisfaction of both the performance criteria described in this Section III and the payment eligibility criteria described in Section V.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance criteria are based on Boston Scientific&#8217;s achievement of the 2021 annual financial plan performance for Free Cash Flow.  Boston Scientific Free Cash Flow will be measured over a one-year performance period beginning January 1, 2022 and ending on December 31, 2022. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Performance Share Units as to which the performance criteria under this program shall be determined to have been satisfied will be in a range of 0% to 150% of the target number of Performance Share Units awarded to the participant as follows&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.108%"><tr><td style="width:1.0%"></td><td style="width:49.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Performance<br>Percent to Plan</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Performance Share Units as a Percent of Target</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">125% or above</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">150%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">110%</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">120%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100%</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90%</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">80%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50%</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less than 50%</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0%</font></td></tr></table></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the minimum level of performance is achieved, the number of Performance Share Units will be calculated linearly between each set of data points. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:249.75pt"><tr><td style="width:1.0pt"></td><td style="width:247.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)<br>Free Cash Flow Performance Share Program<br>(&#8220;FCF Program&#8221;)<br>Performance Period January 1, 2022 - December 31, 2022</font></td></tr></table></div><div style="padding-left:216pt;text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the end of the Performance Period, the Committee shall determine the number of Performance Share Units as to which the performance criteria of this Program have been satisfied, which determination shall be final and binding.  Shares of Common Stock will be delivered or otherwise made available to the participant no later than January 15, 2025 in settlement of the Performance Share Units as to which the performance criteria of this program have been satisfied if and to the extent the payment eligibility criteria of Section V below are also satisfied.  Any Performance Share Units as to which the performance criteria of this Section III have not been satisfied shall be forfeited in their entirety.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">IV.&#160;&#160;&#160;&#160;Definitions</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Boston Scientific Free Cash Flow&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means reported operating cash flow minus capital expenditures and excludes cash flows associated with certain significant and unusual litigation, acquisition, divestiture, restructuring, debt extinguishment, tax-related items and other unusual items consistent with our non-gaap policy.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Performance Period&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the one-year period commencing January 1, 2022 and ending on December 31, 2022.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Service Period&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the three-year period beginning January 1, 2022 and ending on December 31, 2024. </font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">V.&#160;&#160;&#160;&#160;Payment Eligibility Criteria</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth below with respect to a Change in Control or termination of employment due to</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retirement, death or Disability, (i) no Performance Share Units shall vest prior to the end of the Service Period (December 31, 2024) and (ii) a participant must be employed by the Company (as defined below) on December 31, 2024 to be eligible to receive shares of Common Stock in respect of his or her Performance Share Units as to which the performance criteria of this program have been satisfied. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a participant&#8217;s employment with Boston Scientific and its Affiliates (the &#8220;Company&#8221;) terminates or there is a Change in Control before the end of the Performance Period (December 31, 2022), all of his or her Performance Share Units shall be forfeited in their entirety except as set forth below with respect to a termination of employment due to death or Disability.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a participant&#8217;s employment with the Company terminates after the Performance Period but before the end of the Service Period, all of his or her Performance Share Units as to which the performance criteria of this program have been satisfied shall be forfeited in their entirety, except in connection with Retirement, death, Disability or upon a Change in Control as outlined below.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants on military, sick or other bona fide leave of absence on December 31, 2024 will not be deemed to have terminated employment with the Company if such absence does not exceed 180 days or, if longer, the period the participant retains the right by statute or by contract to return to employment with the Company. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a participant&#8217;s employment with the Company terminates due to death or Disability before the end of the Service Period, all of his or her Performance Share Units shall accelerate vesting and shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this program have been satisfied at the end of the Performance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:249.75pt"><tr><td style="width:1.0pt"></td><td style="width:247.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)<br>Free Cash Flow Performance Share Program<br>(&#8220;FCF Program&#8221;)<br>Performance Period January 1, 2022 - December 31, 2022</font></td></tr></table></div><div style="padding-left:216pt;text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Period. The number of shares to be issued to the participant, if any, will be approved by the Committee at its next regular meeting following the later of the participant&#8217;s termination of employment or the end of the Performance Period.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a participant&#8217;s employment with the Company terminates due to Retirement or, subject to the terms of any separate Change in Control or similar agreement to which a participant is bound, there is a Change in Control after the end of the Performance Period but before the end of the Service Period, shares of Common Stock shall be issued in respect of the Performance Share Units as to which the performance criteria of this program have been satisfied within 70 days of the effective date of the termination or Change in Control, as applicable, on a prorated basis using the effective date of the participant&#8217;s termination of employment or the Change in Control, as applicable.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares to be issued on a prorated basis shall be determined as follows&#58; (# Performance Share Units as to which the performance criteria of the FCF Program have been satisfied) * ((# of months worked during the Service Period, rounded to nearest whole month) &#47; 36).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of prorated shares to be issued to the participant, if any, will be approved by the Committee at its next regular meeting.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">VI.&#160;&#160;&#160;&#160;Termination, Suspension or Modification and Interpretation of the FCF Program</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee has sole authority over administration and interpretation of the FCF Program and retains its right to exercise discretion as it sees fit, except that, with respect to Covered Employees, the Committee shall have no discretion to increase the number of shares of Common Stock in which a participant may vest above the amount described in Section III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee may terminate, suspend or modify and if suspended, may reinstate with or without modification all or part of the FCF Program at any time, with or without notice to the participant.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee reserves the exclusive right to determine eligibility to participate in this FCF Program and to interpret all applicable terms and conditions, including eligibility criteria.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">VII.&#160;&#160;&#160;&#160;Recoupment Policy</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General Recoupment Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent permitted by governing law, the Board, in its discretion, may seek Recovery of Performance Share Units granted to a Current Executive Officer or Former Executive Officer if, in the judgment of the Board, such Executive Officer commits misconduct or a gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company while serving in capacity as Executive Officer.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following terms shall have the meaning set forth below&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;&#34;Current Executive Officer&#34; means any individual currently designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 of the Securities Exchange Act of 1934, as amended.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">           </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;&#34;Executive Officer&#34; means any Current Executive Officer or Former Executive Officer.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;&#34;Former Executive Officer&#34; means any individual previously (but not currently) designated as an &#8220;executive officer&#8221; by the Board under Rule 3b-7 of the Securities Exchange Act of 1934, as amended.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Recovery&#34; means the forfeiture or cancellation of unvested Performance Share Units.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:249.75pt"><tr><td style="width:1.0pt"></td><td style="width:247.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Boston Scientific Corporation (&#8220;Boston Scientific&#8221;)<br>Free Cash Flow Performance Share Program<br>(&#8220;FCF Program&#8221;)<br>Performance Period January 1, 2022 - December 31, 2022</font></td></tr></table></div><div style="padding-left:216pt;text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Provisions Required by Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company subsequently determines that it is required by law to apply a &#34;clawback&#34; or alternate recoupment provision to outstanding Performance Share Units, under the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, then such clawback or recoupment provision also shall apply to the Performance Share Units, as applicable, as if it had been included on the date the Performance Share Units were granted and the Company shall notify the participant of such additional provision.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">VIII.&#160;&#160;&#160;&#160;Other</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This document sets forth the terms of the FCF Program and is not intended to be a contract or employment agreement between the participant and the Company.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As applicable, it is understood that both the participant and the Company have the right to terminate the participant&#8217;s employment with the Company at any time, with or without cause and with or without notice, in acknowledgement of the fact that their employment relationship is &#8220;at will.&#8221; </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent section 409A of the Internal Revenue Code (&#8220;Code&#8221;) applies to any award under this FCF Program, the award shall be interpreted in a manner consistent with Code section 409A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where section 409A applies, in the case of any payment made on termination of employment, a termination of employment shall not be deemed to have occurred unless such termination is also a &#8220;separation from service&#8221; within the meaning of Code section 409A and, for purposes of any such provision, references to a &#8220;termination,&#8221; &#8220;termination of employment,&#8221; or like terms shall mean &#8220;separation from service.&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where section 409A applies, in the case of a payment made upon a Change in Control, a Change in Control shall not be deemed to have occurred unless there is a change in the ownership or effective control of Boston Scientific, or in the ownership of a substantial portion of the assets of Boston Scientific, as defined in Code section 409A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where required by section 409A in the case of a specified employee (as determined under Code section 409A), payments on termination shall be made on the first business day of the seventh month following termination.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>logo2021compensationplans.jpg
<TEXT>
begin 644 logo2021compensationplans.jpg
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MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\U_P#@LE_S2'_N,?\
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M1111111111111111111111111111111111111111111117YK_P#!9+_FD/\
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M4 K]Z*$]V.&8?=P"''ZQZ;IMIHVGVUA86T-E8VL2PP6UN@2.*-1A551P
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MC#_HGVA_^!DU<;XM_P""KWQBUZU>#2;'PWX:W+@7%I9//,I]1YTC)^:5WO\
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MO_P3ST3XDW-NM_\ '7P/(SD$V'AF\74+D\\KAFC*GWVL/K7W]\#_ -A/X2_
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M^&)/@5_T3+0_^_;_ /Q5'_#$GP*_Z)EH?_?M_P#XJM[P+^S#\+/AGXDM]?\
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M1111111111111111111111111111111111111111111117YK_P#!9+_FD/\
MW&/_ &RK\UZ*^\/^"0?_ "6WQE_V+Q_]*8:_6"BBBBOA7_@KAX)CUCX'^&?$
MJH&NM%UH0;O[L-Q$P?\ \?BAK\F:*]6_93\>3?#7]HWX>Z]%(T4<>L06]PR\
MG[/,WDS#'?\ =R/7[\U^(W_!1S6GUG]L#QPI<O%9K96L0;/RA;2$L/\ OMG_
M #KYIHK]\_V1/^37_A;_ -B]9_\ HH5Z[1117#_'3_DB7Q!_[%[4/_2:2OYY
MJ6O</V(=:;0?VL/AG<HS*9-56U^7TF1X2.OI(:_=^OD?_@HY^S/=?'3X3P:]
MX?M6NO%GA7S+F"WB7+W=LP'G0@=2PV*ZCGE64#+U^-!&TX(P111117JWP-_:
M@^(O[/>J1W'A+7IH]/#[IM%O"9K&XYY#1$\$_P!Y"K>]?L)^RG^UKX8_:B\)
MO<V &D^)[%5_M/0Y9 SQ9X\R,\;XB>C8R#P0.,^[45XA^VW_ ,FH?$W_ +!+
M?^AK7X/45]O?\$B_^3D?$G_8IW/_ *66=?KE117\X_C/6CXD\8:[JS/YC7]_
M/=%^?F+R,V>>>_>L>NA^'=O'=_$#PQ!,N^*75+5'7U4RJ"/RK^B^BBBBOD;_
M (*D?\FH7_\ V%K+_P!#-?C117W;_P $A=8EA^.7C#2@3Y%SX<:Y8=MT5U J
M_I,U?K'7D7[7?_)K_P 4O^Q>O/\ T4:_ RBOLO\ X)0_\G077_8O7?\ Z-@K
M]A:***_/S_@L'_R3?X??]A:?_P!$BORRHK].O^".O_(M_%#_ *^]/_\ 0)Z_
M1:BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOS7_X+)?\TA_[
MC'_ME7YKT5]X?\$@_P#DMOC+_L7C_P"E,-?K!11117RO_P %-%#?LA>*"5!*
MWE@02.G^DQU^*]%6]'DFAU:RDMHQ+<+.ACC/1F## _$XK^D2OPV_X*"6TEK^
MV%\1TE7:QN+60#(/RM9P,I_$$5\\T5^^?[(G_)K_ ,+?^Q>L_P#T4*]=HHHK
MA_CI_P D2^(/_8O:A_Z325_//17L/['MM)=?M2?"Y(EWL-?M9",@?*KAF/X
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ME_Z&:_&BBON#_@D7$_\ PT9XFD",8U\*7"EL< F\L\#/KP?R-?KA7D7[7?\
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M7G_HHU^!E%?9?_!*'_DZ"Z_[%Z[_ /1L%?L+1117Y^?\%@_^2;_#[_L+3_\
MHD5^65%?IU_P1U_Y%OXH?]?>G_\ H$]?HM117YS?\%/OVM9M'BE^#OA2\,5S
M<1+)XBO+=\,D;#*6@(Y!889_]DJO(9A7YD5])?L%_LWQ_M$?&J"+5K<S>$=
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M%9[:\MG#QRQL,AE(ZBM&BJNI:E::-I]S?W]S#96-K$TT]S<.$CBC499F8\
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M^!/CQX^\.Z%XX^PZ/I>LW-I9VW]DV,GEQ)(0J[G@+' [DD^]>=?\/'/VB?\
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M)J.JW;=\B.%/X8HE_@1>RCZG)))@^&/P[U?XM?$#0O"&@Q"75=7NEMH=V=J
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MS?'/_DMGQ!_[&'4/_2F2N(HK^ACX%_\ )$OA]_V+VG_^DT==Q111117XJ_\
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M )+9\0?^QAU#_P!*9*XBBOZ&/@7_ ,D2^'W_ &+VG_\ I-'7<444445^*O\
MP4R_Y.^\4_\ 7I8?^DL=?+-%?M3_ ,$S?^30?"W_ %]W_P#Z525]3T445S7Q
M-_Y)OXL_[!-W_P"B7K^=2BBOZ4*****_'K_@J]_R=!:_]B]:?^C9Z^-**_7+
M_@D7_P FW>)/^QLN?_2.SK[>KY=_X*673V_['OC&-,;9Y["-\CL+R%OYJ*_%
M&BBOZ*_AE_R3?PG_ -@FT_\ 1*5TM%%%%%%%%>1?M=_\FO\ Q2_[%Z\_]%&O
MP1L[R;3[N"ZMI&AN('66.1>JLIR"/<$"OZ(OA;XWM_B5\-_#'BNU*F'6=-M[
MX!>BEXPS+]5)(/N*ZFBBBBBBBBLWQ)X?LO%GAW5=#U*+SM.U.UELKF/^_%(A
M1Q^*L:_G5\5^'KCPCXHUC0KH@W6EWDUE*0, O&[(WZJ:RZ_:_P#X)JVCVW['
MO@V1\;;B>_D3'H+R9>?Q4U]&^*-/_M?PSJ]@8_.^U6DT'EYQNW(5QGMG-?SA
M4M%?M3_P3-_Y-!\+?]?=_P#^E4E?4]%%%%%%%%%>1?M=_P#)K_Q2_P"Q>O/_
M $4:_ RBO2OV9?\ DY'X4?\ 8V:3_P"ED5?T#45P7Q^TTZQ\"?B/IZAB;KPW
MJ4 $8^;YK61>/?FOY[***_<[]@/_ )-!^&__ %Z3_P#I5-7T%1111111117S
M[^WY_P F@_$C_KT@_P#2J&OPQHKV_P#8D_Y.O^&7_867_P! :OWAHHHHKQ#]
MMO\ Y-0^)O\ V"6_]#6OP>HKUS]D7_DZ#X6_]C#9_P#HU:_?2BBBOYYOCG_R
M6SX@_P#8PZA_Z4R5Q%%?T,? O_DB7P^_[%[3_P#TFCKN******_%7_@IE_R=
M]XI_Z]+#_P!)8Z^6:*_:G_@F;_R:#X6_Z^[_ /\ 2J2OJ>BBBN:^)O\ R3?Q
M9_V";O\ ]$O7\ZE%%?TH44445^/7_!5[_DZ"U_[%ZT_]&SU\:45^N7_!(O\
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M[(O_ "=!\+?^QAL__1JU^^E%%%?SS?'/_DMGQ!_[&'4/_2F2N(HK^ACX%_\
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M)>OYU***_I0HHHHK\>O^"KW_ "=!:_\ 8O6G_HV>OC2BOUR_X)%_\FW>)/\
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M;QE%/]W>>0P-?HO117S[^WY_R:#\2/\ KT@_]*H:_#&BO;_V)/\ DZ_X9?\
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M+?&3X1^(/@;\1-7\'^)+8P:A828250?+N83_ *N:,]T8<CN.0<$$#BZ^J_\
M@GC^TU;?L_\ Q;DTW7[K[-X/\3*EK>S.?DM9U)\B<^B@LRL>RON/W:_:*.19
M45T971AE64Y!![BGT45B>-/&FA_#OPOJ/B+Q'J4&D:-I\1FN+NX;"HH[#N6)
MP HR22  2:_$O]LK]J[4?VHOB&+J%)M/\(:66AT?3I#\P4XW3R@''F/@=.%
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M)FTJV>UB333$%=6;<2V]&YSZ5XM_PZ#^&_\ T.?BK\[;_P"-4?\ #H/X;_\
M0Y^*OSMO_C5'_#H/X;_]#GXJ_.V_^-4?\.@_AO\ ]#GXJ_.V_P#C5'_#H/X;
M_P#0Y^*OSMO_ (U1_P .@_AO_P!#GXJ_.V_^-4?\.@_AO_T.?BK\[;_XU7VS
MX0\-P>#?">BZ!:RR3VVE6,%C%)-C>ZQ1J@9L #)"\XKRW]IW]EGP_P#M2Z#H
MNE:_JVI:3#I5R]S$^FF/<[,NTAMZMQCTKYX_X=!_#?\ Z'/Q5^=M_P#&J/\
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MS\5?G;?_ !JC_AT'\-_^AS\5?G;?_&J/^'0?PW_Z'/Q5^=M_\:H_X=!_#?\
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2*********************__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>percentileperformancecalcu.jpg
<TEXT>
begin 644 percentileperformancecalcu.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  X (L# 2(  A$! Q$!_\0
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M%X+\;?$K5]7_ +,-IXKUF/5X%L;F222WVV=M:^6P:)0<BV#[@>KXQQD^HT4
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' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>bsx-20211119.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:be80d975-5a36-4151-ae87-5223c67bc7de,g:facc5304-55c5-463f-879e-772c005c0ada-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bsx="http://www.bostonscientific.com/20211119" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bostonscientific.com/20211119">
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bsx-20211119_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bsx-20211119_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bsx-20211119_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverDocument" roleURI="http://www.bostonscientific.com/role/CoverDocument">
        <link:definition>0001001 - Document - Cover Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bsx_SeniorNotedue2027Member" abstract="true" name="SeniorNotedue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bsx_A550MCPSSeriesAMember" abstract="true" name="A550MCPSSeriesAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>bsx-20211119_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:be80d975-5a36-4151-ae87-5223c67bc7de,g:facc5304-55c5-463f-879e-772c005c0ada-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bostonscientific.com/role/CoverDocument" xlink:type="simple" xlink:href="bsx-20211119.xsd#CoverDocument"/>
  <link:definitionLink xlink:role="http://www.bostonscientific.com/role/CoverDocument" xlink:type="extended" id="id7cf915a14154ab984cb1fb2a2746600_CoverDocument">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_078726fc-ed8d-411d-8abd-e99acc389181" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_DocumentType_078726fc-ed8d-411d-8abd-e99acc389181" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_49638ec6-0431-4687-a987-5352f5bb9f12" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_DocumentPeriodEndDate_49638ec6-0431-4687-a987-5352f5bb9f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9643231f-9274-45ff-b318-254346decf96" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityRegistrantName_9643231f-9274-45ff-b318-254346decf96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0d706ecf-485e-4d89-b424-acb5a5c291c1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_AmendmentFlag_0d706ecf-485e-4d89-b424-acb5a5c291c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d4009f74-131e-40a7-a171-c0d9eaa4a5bc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d4009f74-131e-40a7-a171-c0d9eaa4a5bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_cffa2b9a-5e00-4341-9e63-7e9495c6fad5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityFileNumber_cffa2b9a-5e00-4341-9e63-7e9495c6fad5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1ce37cea-b564-4d84-8732-7f5b797610ac" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityTaxIdentificationNumber_1ce37cea-b564-4d84-8732-7f5b797610ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1b21e86d-c01f-4625-927c-925b0741ae5b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityAddressAddressLine1_1b21e86d-c01f-4625-927c-925b0741ae5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bb20215b-ba65-460b-b7c6-c9d0a04f35e9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityAddressCityOrTown_bb20215b-ba65-460b-b7c6-c9d0a04f35e9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c6958081-39e9-4855-8f72-efbc49653d54" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityAddressStateOrProvince_c6958081-39e9-4855-8f72-efbc49653d54" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a9995c90-925c-4c67-9768-ef133642ab21" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityAddressPostalZipCode_a9995c90-925c-4c67-9768-ef133642ab21" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6c174919-bb5d-42bf-af6c-cd78d97771f0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_CityAreaCode_6c174919-bb5d-42bf-af6c-cd78d97771f0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7ac8bac2-4943-41ca-9c54-c599f4a3fd95" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_LocalPhoneNumber_7ac8bac2-4943-41ca-9c54-c599f4a3fd95" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_fa812733-9a3b-48c4-8228-49ccb9633b94" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_WrittenCommunications_fa812733-9a3b-48c4-8228-49ccb9633b94" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_8563ae2c-6056-4eac-a4c7-817bd192ca2b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_SolicitingMaterial_8563ae2c-6056-4eac-a4c7-817bd192ca2b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_1b7b15c3-ee5b-433e-91fd-6f037e8275bd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_PreCommencementTenderOffer_1b7b15c3-ee5b-433e-91fd-6f037e8275bd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f17a41b8-23cf-449c-97fc-c0beffe3fe1f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f17a41b8-23cf-449c-97fc-c0beffe3fe1f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_127957b6-cd30-4f1a-9cf5-18b69c021347" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_Security12bTitle_127957b6-cd30-4f1a-9cf5-18b69c021347" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cf8e7dc1-aed2-4740-a6e3-cfe6ffc4bf8d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_TradingSymbol_cf8e7dc1-aed2-4740-a6e3-cfe6ffc4bf8d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_af6ad4a1-31d9-4249-a429-1e52bf49e9b6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_SecurityExchangeName_af6ad4a1-31d9-4249-a429-1e52bf49e9b6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1109408e-b29a-4ce7-aceb-2fe0fa06c978" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityEmergingGrowthCompany_1109408e-b29a-4ce7-aceb-2fe0fa06c978" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8f075dd1-9c95-47c2-a8be-32ea835e5ca1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityCentralIndexKey_8f075dd1-9c95-47c2-a8be-32ea835e5ca1" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_c49053df-9723-42ec-9e67-a71135225dc7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntitiesTable_c49053df-9723-42ec-9e67-a71135225dc7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_09c99805-2a32-4682-a62a-0e77b6a9aad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_c49053df-9723-42ec-9e67-a71135225dc7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_09c99805-2a32-4682-a62a-0e77b6a9aad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_09c99805-2a32-4682-a62a-0e77b6a9aad6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_09c99805-2a32-4682-a62a-0e77b6a9aad6" xlink:to="loc_us-gaap_ClassOfStockDomain_09c99805-2a32-4682-a62a-0e77b6a9aad6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_276177c2-0051-477f-8b0a-96322baa9cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_09c99805-2a32-4682-a62a-0e77b6a9aad6" xlink:to="loc_us-gaap_ClassOfStockDomain_276177c2-0051-477f-8b0a-96322baa9cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cffa2fbc-7cad-4f6c-adf4-881e9d3f4a73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_276177c2-0051-477f-8b0a-96322baa9cad" xlink:to="loc_us-gaap_CommonStockMember_cffa2fbc-7cad-4f6c-adf4-881e9d3f4a73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SeniorNotedue2027Member_0c10a3ea-0054-4d49-b5ee-d50d555f81a8" xlink:href="bsx-20211119.xsd#bsx_SeniorNotedue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_276177c2-0051-477f-8b0a-96322baa9cad" xlink:to="loc_bsx_SeniorNotedue2027Member_0c10a3ea-0054-4d49-b5ee-d50d555f81a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A550MCPSSeriesAMember_87f8292d-4d65-444f-98ec-431fcf6dc18e" xlink:href="bsx-20211119.xsd#bsx_A550MCPSSeriesAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_276177c2-0051-477f-8b0a-96322baa9cad" xlink:to="loc_bsx_A550MCPSSeriesAMember_87f8292d-4d65-444f-98ec-431fcf6dc18e" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>bsx-20211119_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:be80d975-5a36-4151-ae87-5223c67bc7de,g:facc5304-55c5-463f-879e-772c005c0ada-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_bsx_A550MCPSSeriesAMember_40963712-79f5-433b-92bb-b299715c2c0a_terseLabel_en-US" xlink:label="lab_bsx_A550MCPSSeriesAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% MCPS, Series A [Member]</link:label>
    <link:label id="lab_bsx_A550MCPSSeriesAMember_label_en-US" xlink:label="lab_bsx_A550MCPSSeriesAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% MCPS, Series A [Member]</link:label>
    <link:label id="lab_bsx_A550MCPSSeriesAMember_documentation_en-US" xlink:label="lab_bsx_A550MCPSSeriesAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% MCPS, Series A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A550MCPSSeriesAMember" xlink:href="bsx-20211119.xsd#bsx_A550MCPSSeriesAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_A550MCPSSeriesAMember" xlink:to="lab_bsx_A550MCPSSeriesAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e688b48b-00cc-4365-a666-5c59c815144a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a4785b1e-3ed0-4962-a134-6cdb2947431f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d2dece3e-74bb-4fd2-a573-b797dfda15be_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_603d2129-a8ce-4920-839d-259e973b2d3d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_1082b6c9-6de8-4a84-a60f-e510f5fa719b_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6aeb15fb-87ad-4599-bfb6-97ac79d764d2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2a304803-6c13-4391-babd-877a67dc232f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b90732fd-45a0-4a7b-b187-a7e1f6c7df9e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_5d8ce9df-4549-4686-9a25-554547a3a670_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_416508ee-8598-4e94-9b90-7fc0abc60f1d_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8bd939bc-67cb-4db6-b7b1-14f16d185097_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2e665df1-96cd-44cd-9aa5-d4d9e050c995_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bsx_SeniorNotedue2027Member_0c0c63b7-cd2e-45f2-b1e1-69c187fba816_terseLabel_en-US" xlink:label="lab_bsx_SeniorNotedue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Note due 2027 [Member]</link:label>
    <link:label id="lab_bsx_SeniorNotedue2027Member_label_en-US" xlink:label="lab_bsx_SeniorNotedue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Note due 2027 [Member]</link:label>
    <link:label id="lab_bsx_SeniorNotedue2027Member_documentation_en-US" xlink:label="lab_bsx_SeniorNotedue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Note due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SeniorNotedue2027Member" xlink:href="bsx-20211119.xsd#bsx_SeniorNotedue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bsx_SeniorNotedue2027Member" xlink:to="lab_bsx_SeniorNotedue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_7f32c100-7f91-4c1f-852f-d4537ce4b328_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_09080663-ec43-42b7-94c8-9c5a24a132f3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2639b6de-4dbf-4942-941e-0fbe0131baa6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9712ef43-6662-4dbd-85fb-8e4b1c7c499a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_013afb51-6945-4d3f-8663-7e5ad477ad89_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5ba9c700-d243-48a1-b5d1-7d9300f97951_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_d978db16-a977-4141-916c-0308e7b1b469_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_47ac2ab8-c6a5-4680-87c0-0f4c800f9ccc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_486113e4-8f7b-45cb-b18a-c73aa583fad8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_95bfe48e-3feb-4a2e-ad3f-b3a6c0921006_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a4790593-4b42-4688-aa7c-37d253c46b9e_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_d5ae1cea-ef6a-45a2-8c80-4cfe49e07ba4_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f41dce9a-d22f-4708-9a7c-2f5e1c332a85_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_74e65727-20ae-45f8-be58-92f03ae2e802_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a94fe167-8f37-48a2-909e-f5ed59927f27_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_f19cd57a-e0ce-457b-9735-198edf1df311_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>bsx-20211119_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:be80d975-5a36-4151-ae87-5223c67bc7de,g:facc5304-55c5-463f-879e-772c005c0ada-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bostonscientific.com/role/CoverDocument" xlink:type="simple" xlink:href="bsx-20211119.xsd#CoverDocument"/>
  <link:presentationLink xlink:role="http://www.bostonscientific.com/role/CoverDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b55f7459-ca67-4340-a0eb-2a857e9dcbd0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_c49053df-9723-42ec-9e67-a71135225dc7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b55f7459-ca67-4340-a0eb-2a857e9dcbd0" xlink:to="loc_dei_EntitiesTable_c49053df-9723-42ec-9e67-a71135225dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_09c99805-2a32-4682-a62a-0e77b6a9aad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_c49053df-9723-42ec-9e67-a71135225dc7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_09c99805-2a32-4682-a62a-0e77b6a9aad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_276177c2-0051-477f-8b0a-96322baa9cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_09c99805-2a32-4682-a62a-0e77b6a9aad6" xlink:to="loc_us-gaap_ClassOfStockDomain_276177c2-0051-477f-8b0a-96322baa9cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cffa2fbc-7cad-4f6c-adf4-881e9d3f4a73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_276177c2-0051-477f-8b0a-96322baa9cad" xlink:to="loc_us-gaap_CommonStockMember_cffa2fbc-7cad-4f6c-adf4-881e9d3f4a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_SeniorNotedue2027Member_0c10a3ea-0054-4d49-b5ee-d50d555f81a8" xlink:href="bsx-20211119.xsd#bsx_SeniorNotedue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_276177c2-0051-477f-8b0a-96322baa9cad" xlink:to="loc_bsx_SeniorNotedue2027Member_0c10a3ea-0054-4d49-b5ee-d50d555f81a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bsx_A550MCPSSeriesAMember_87f8292d-4d65-444f-98ec-431fcf6dc18e" xlink:href="bsx-20211119.xsd#bsx_A550MCPSSeriesAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_276177c2-0051-477f-8b0a-96322baa9cad" xlink:to="loc_bsx_A550MCPSSeriesAMember_87f8292d-4d65-444f-98ec-431fcf6dc18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_c49053df-9723-42ec-9e67-a71135225dc7" xlink:to="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_078726fc-ed8d-411d-8abd-e99acc389181" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_DocumentType_078726fc-ed8d-411d-8abd-e99acc389181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_49638ec6-0431-4687-a987-5352f5bb9f12" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_DocumentPeriodEndDate_49638ec6-0431-4687-a987-5352f5bb9f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9643231f-9274-45ff-b318-254346decf96" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityRegistrantName_9643231f-9274-45ff-b318-254346decf96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0d706ecf-485e-4d89-b424-acb5a5c291c1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_AmendmentFlag_0d706ecf-485e-4d89-b424-acb5a5c291c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d4009f74-131e-40a7-a171-c0d9eaa4a5bc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d4009f74-131e-40a7-a171-c0d9eaa4a5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_cffa2b9a-5e00-4341-9e63-7e9495c6fad5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityFileNumber_cffa2b9a-5e00-4341-9e63-7e9495c6fad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1ce37cea-b564-4d84-8732-7f5b797610ac" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityTaxIdentificationNumber_1ce37cea-b564-4d84-8732-7f5b797610ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1b21e86d-c01f-4625-927c-925b0741ae5b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityAddressAddressLine1_1b21e86d-c01f-4625-927c-925b0741ae5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bb20215b-ba65-460b-b7c6-c9d0a04f35e9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityAddressCityOrTown_bb20215b-ba65-460b-b7c6-c9d0a04f35e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c6958081-39e9-4855-8f72-efbc49653d54" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityAddressStateOrProvince_c6958081-39e9-4855-8f72-efbc49653d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a9995c90-925c-4c67-9768-ef133642ab21" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityAddressPostalZipCode_a9995c90-925c-4c67-9768-ef133642ab21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6c174919-bb5d-42bf-af6c-cd78d97771f0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_CityAreaCode_6c174919-bb5d-42bf-af6c-cd78d97771f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7ac8bac2-4943-41ca-9c54-c599f4a3fd95" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_LocalPhoneNumber_7ac8bac2-4943-41ca-9c54-c599f4a3fd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_fa812733-9a3b-48c4-8228-49ccb9633b94" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_WrittenCommunications_fa812733-9a3b-48c4-8228-49ccb9633b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_8563ae2c-6056-4eac-a4c7-817bd192ca2b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_SolicitingMaterial_8563ae2c-6056-4eac-a4c7-817bd192ca2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_1b7b15c3-ee5b-433e-91fd-6f037e8275bd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_PreCommencementTenderOffer_1b7b15c3-ee5b-433e-91fd-6f037e8275bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f17a41b8-23cf-449c-97fc-c0beffe3fe1f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f17a41b8-23cf-449c-97fc-c0beffe3fe1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_127957b6-cd30-4f1a-9cf5-18b69c021347" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_Security12bTitle_127957b6-cd30-4f1a-9cf5-18b69c021347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cf8e7dc1-aed2-4740-a6e3-cfe6ffc4bf8d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_TradingSymbol_cf8e7dc1-aed2-4740-a6e3-cfe6ffc4bf8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_af6ad4a1-31d9-4249-a429-1e52bf49e9b6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_SecurityExchangeName_af6ad4a1-31d9-4249-a429-1e52bf49e9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1109408e-b29a-4ce7-aceb-2fe0fa06c978" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityEmergingGrowthCompany_1109408e-b29a-4ce7-aceb-2fe0fa06c978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8f075dd1-9c95-47c2-a8be-32ea835e5ca1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b1b40779-5b7d-42d3-81f1-5af30e0e039a" xlink:to="loc_dei_EntityCentralIndexKey_8f075dd1-9c95-47c2-a8be-32ea835e5ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>bsx-20211119_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bsx="http://www.bostonscientific.com/20211119"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bsx-20211119.xsd" xlink:type="simple"/>
    <context id="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="ib3c93072d72f4bb58bc058d6d4cabeef_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i73fddac06dfe4a60a37ab77cd173606b_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:SeniorNotedue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="ibe3dd1c6aa0544edbbf102eabcc07135_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bsx:A550MCPSSeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV80L2ZyYWc6ZWM0MzhlODAzYjM1NGM2ZDliNzM5OWUxNDM5ZDIzYzIvdGFibGU6YWZiYWU3ZDFmMTNlNGY1MGJlNTg2NjEzNjA4MmExMmMvdGFibGVyYW5nZTphZmJhZTdkMWYxM2U0ZjUwYmU1ODY2MTM2MDgyYTEyY18yLTEtMS0xLTM5Nzkz_9a43e5c1-fbbb-4d46-abc9-dca751288d4d">0000885725</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV80L2ZyYWc6ZWM0MzhlODAzYjM1NGM2ZDliNzM5OWUxNDM5ZDIzYzIvdGFibGU6YWZiYWU3ZDFmMTNlNGY1MGJlNTg2NjEzNjA4MmExMmMvdGFibGVyYW5nZTphZmJhZTdkMWYxM2U0ZjUwYmU1ODY2MTM2MDgyYTEyY181LTEtMS0xLTM5Nzkz_4311087e-bc6a-41c9-9134-ebc4b4dd0727">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDM5_5faba540-42cb-462c-8132-db4862d07195">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8zNjQ_b15a8ca0-5173-4c02-9701-4df1df01db2e">2021-11-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQw_bbfc75c8-829c-4f77-8047-949f091ad3d2">BOSTON SCIENTIFIC CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6M2UwNTc1NmMzYzk2NGEyYmJlOTNiOTYzM2IzNjY1NDYvdGFibGVyYW5nZTozZTA1NzU2YzNjOTY0YTJiYmU5M2I5NjMzYjM2NjU0Nl8wLTAtMS0xLTM5Nzkz_60f708c1-061e-486b-a27a-3f07cd44476f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6M2UwNTc1NmMzYzk2NGEyYmJlOTNiOTYzM2IzNjY1NDYvdGFibGVyYW5nZTozZTA1NzU2YzNjOTY0YTJiYmU5M2I5NjMzYjM2NjU0Nl8wLTItMS0xLTM5Nzkz_02352e69-e63b-4cee-b844-67da16aca43a">1-11083</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6M2UwNTc1NmMzYzk2NGEyYmJlOTNiOTYzM2IzNjY1NDYvdGFibGVyYW5nZTozZTA1NzU2YzNjOTY0YTJiYmU5M2I5NjMzYjM2NjU0Nl8wLTYtMS0xLTM5Nzkz_69b94f7d-e424-4acd-83bf-b9d55a26e4b8">04-2695240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQ0_adea024b-fe6b-4d8e-84f0-78f5598e7482">300 Boston Scientific Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQ1_db8e788a-93a2-49c9-802c-e9b2347212e7">Marlborough</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQx_49cd3647-3a05-46e8-933b-9528177d72df">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQy_988f47cd-4ac0-4092-9146-dd7227d0fbc5">01752-1234</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQ2_a429c712-3b4d-496a-aaba-d110f59c7131">508</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQz_bc152a79-2c1f-4912-9233-af26abaf8c6c">683-4000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6ODQyYjE4OTc4ZDM5NGMwOTgzNDY1YmQyMGZmNDA4OGMvdGFibGVyYW5nZTo4NDJiMTg5NzhkMzk0YzA5ODM0NjViZDIwZmY0MDg4Y18wLTAtMS0xLTM5Nzkz_2e9a7da7-4c3a-4de1-8d9c-7e1b71345677">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6ODQyYjE4OTc4ZDM5NGMwOTgzNDY1YmQyMGZmNDA4OGMvdGFibGVyYW5nZTo4NDJiMTg5NzhkMzk0YzA5ODM0NjViZDIwZmY0MDg4Y18yLTAtMS0xLTM5Nzkz_6f186b78-571b-4a83-b031-e5cfc1c71549">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6ODQyYjE4OTc4ZDM5NGMwOTgzNDY1YmQyMGZmNDA4OGMvdGFibGVyYW5nZTo4NDJiMTg5NzhkMzk0YzA5ODM0NjViZDIwZmY0MDg4Y180LTAtMS0xLTM5Nzkz_4098541e-11a7-4324-b90a-0d6e89d5a720">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6ODQyYjE4OTc4ZDM5NGMwOTgzNDY1YmQyMGZmNDA4OGMvdGFibGVyYW5nZTo4NDJiMTg5NzhkMzk0YzA5ODM0NjViZDIwZmY0MDg4Y182LTAtMS0xLTM5Nzkz_0cdb60a0-e52b-4e31-a982-5499386683e4">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ib3c93072d72f4bb58bc058d6d4cabeef_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8xLTAtMS0xLTM5Nzkz_11434499-2e2b-43aa-ae2a-b233498df4bd">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib3c93072d72f4bb58bc058d6d4cabeef_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8xLTItMS0xLTM5Nzkz_9d7078f1-dcf7-45b3-af3f-a067fe214330">BSX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib3c93072d72f4bb58bc058d6d4cabeef_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8xLTQtMS0xLTM5Nzkz_e0cb12dc-6a2f-4012-8428-bd4a4eba3869">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i73fddac06dfe4a60a37ab77cd173606b_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8yLTAtMS0xLTM5Nzkz_6c607125-5e4f-4d5b-b84c-57a6f8a4f572">0.625% Senior Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i73fddac06dfe4a60a37ab77cd173606b_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8yLTItMS0xLTM5Nzkz_5be35b91-9ce1-4999-9e62-00a8d8289514">BSX27</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i73fddac06dfe4a60a37ab77cd173606b_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8yLTQtMS0xLTM5Nzkz_d22b5af5-8763-4281-9cb1-f584bfbe7ab7">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ibe3dd1c6aa0544edbbf102eabcc07135_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8zLTAtMS0xLTM5Nzkz_27ae7736-fefb-43b9-ae55-7ceaf8608fec">5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibe3dd1c6aa0544edbbf102eabcc07135_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8zLTItMS0xLTM5Nzkz_7ef5a048-854d-468f-81ad-8f65ad3f1051">BSX PR A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibe3dd1c6aa0544edbbf102eabcc07135_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGFibGU6YTRmMzcxOGU3NzM0NDg3M2I3YTFhNmNkODJmOWJmYTIvdGFibGVyYW5nZTphNGYzNzE4ZTc3MzQ0ODczYjdhMWE2Y2Q4MmY5YmZhMl8zLTQtMS0xLTM5Nzkz_1124b560-f795-4cde-9f1e-f623e6a2cba5">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i1342fd7c290c47c88691b8dd99398942_D20211119-20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmIzM2I1MTdiNTgyNDQyYTBiZGJjZjdkMzBkYWJmZjBlL3NlYzpiMzNiNTE3YjU4MjQ0MmEwYmRiY2Y3ZDMwZGFiZmYwZV8xL2ZyYWc6OTg0OTY1YTQ1NmUzNDAxZWIwMjQ5YTlhYjA2OWJkNGEvdGV4dHJlZ2lvbjo5ODQ5NjVhNDU2ZTM0MDFlYjAyNDlhOWFiMDY5YmQ0YV8xNDQ3_b2e9ed05-3486-4eed-8f06-e4b22e3cc2b8">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139700719771464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Document<br></strong></div></th>
<th class="th"><div>Nov. 19, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 19,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BOSTON SCIENTIFIC CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-2695240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">300 Boston Scientific Way<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Marlborough<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01752-1234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">683-4000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000885725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BSX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bsx_SeniorNotedue2027Member', window );">Senior Note due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Senior Notes due 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BSX27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember', window );">5.50% MCPS, Series A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BSX PR A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bsx_SeniorNotedue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bsx_SeniorNotedue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bsx_A550MCPSSeriesAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
MIX%W4W1&*$4A!0  :A8  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RU
MF&^/XC80QE]?/X6%>E(K+9 X_-L3BP3L[A7=+2"@W;:GOC") >L2FSH.+-^^
MDQ 2VH8)J[M] PEDGOP\'C^>I+M7^FNXX=R0E\"7X5UE8\SV0[T>NAL>L+"F
MMES"/RNE V;@5*_KX59SYB5!@5^GEM6J!TS(2J^;_#;5O:Z*C"\DGVH21D'
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M3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;
M 4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " "G@7=3EXJ[',     3 @
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MY68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B?
M:ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G6
M0VY6= 9.QL4NF+ZT*8>0HNYN*N,YZH WY>!S-%="A0'*-]6+RFM1Q9:3[NAU
MIO</DT<MI'5NI=Q[>"5;CEG'?UK^ %!+ P04    " "G@7=3)!Z;HJT   #X
M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *>!=U.%KT4A[0   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *>!
M=U.97)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ IX%W4W1&*$4A!0  :A8  !@
M ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *>!
M=U.?H!OPL0(  .(,   -              "  6,-  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ IX%W4Y>*NQS     $P(   L              ( !/Q
M %]R96QS+RYR96QS4$L! A0#%     @ IX%W4S?4:_XV 0  *P(   \
M         ( !*!$  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *>!=U,D
M'INBK0   /@!   :              "  8L2  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( *>!=U-ED'F2&0$  ,\#   3
M      "  7 3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
' +H4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>4</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>3</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bsx-20211119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bostonscientific.com/role/CoverDocument</Role>
      <ShortName>Cover Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="bsx-20211119.htm">bsx-20211119.htm</File>
    <File>bsx-20211119.xsd</File>
    <File>bsx-20211119_def.xml</File>
    <File>bsx-20211119_lab.xml</File>
    <File>bsx-20211119_pre.xml</File>
    <File>exhibit101bostonscientific.htm</File>
    <File>exhibit102bostonscientific.htm</File>
    <File>exhibit103bostonscientific.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bsx-20211119.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 4,
   "dts": {
    "definitionLink": {
     "local": [
      "bsx-20211119_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "bsx-20211119.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bsx-20211119_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bsx-20211119_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bsx-20211119.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 30,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 2,
   "memberStandard": 1,
   "nsprefix": "bsx",
   "nsuri": "http://www.bostonscientific.com/20211119",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20211119.htm",
      "contextRef": "i1342fd7c290c47c88691b8dd99398942_D20211119-20211119",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Document",
     "role": "http://www.bostonscientific.com/role/CoverDocument",
     "shortName": "Cover Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bsx-20211119.htm",
      "contextRef": "i1342fd7c290c47c88691b8dd99398942_D20211119-20211119",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 3,
   "tag": {
    "bsx_A550MCPSSeriesAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% MCPS, Series A",
        "label": "5.50% MCPS, Series A [Member]",
        "terseLabel": "5.50% MCPS, Series A [Member]"
       }
      }
     },
     "localname": "A550MCPSSeriesAMember",
     "nsuri": "http://www.bostonscientific.com/20211119",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "bsx_SeniorNotedue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Note due 2027 [Member]",
        "label": "Senior Note due 2027 [Member]",
        "terseLabel": "Senior Note due 2027 [Member]"
       }
      }
     },
     "localname": "SeniorNotedue2027Member",
     "nsuri": "http://www.bostonscientific.com/20211119",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bostonscientific.com/role/CoverDocument"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0000885725-21-000056-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000885725-21-000056-xbrl.zip
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M%#\%GA!S+"%\0&RE/-VO_V=^6RQ6WBM^-=_Z$,@;>\5/(""2[ !4G3T<E*3
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M62H@,I2&.,DEL=XIJSPWS.<(QP\&W7ND3S?A-DLQ_LMZC#5N=]%VR]F=#!A
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M:PB;R]-SM/P_ID=L$J\J:S@M3357T]+5R5+&:SB6.GW*\GT&,M[/P'H^4L.
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M0RDXL>(,H[>27%NH(R17,S>9Y-J"V)5<Z^_M)7>A9"NT='];TIN%<(7DTI,
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M[.6+,+H04?CCO>AP$#[>[S\^'H2'3Q\].SJ2AT?/GLA'3Y[V^T^>/I%'_W<
M@]R#K_,U)IO%ZL=[XRC9&2E\_O,GAY/L9!J%V>CYP?[^#_<JW\O4EVQ'QM$P
M>?YW;K)H,(//,]F/E?M&/]6ATCM!&L=R8M1S]\-)&)E)+&?/HR2.$K5#%YV,
MI1["H_MIEJ7CY\?PY NELRB0L7T*/9 _+@>UN\\#RS3\/W1/MA_OTD=[6=C\
M[/#9[L'3IYT?[^\>='XV][;'<-O#&[_MH\/=HZ/NC_W;[M%,\&S A)N)3'Z\
M=W2OMB9VE@\FF3!I'(7B/LSCR42&(0CD\WT!'_!JOWP1C8="QMF/]^)TF*)$
M!NEXHA(C<4O ,B9F]^_)$!Z@@\7?X4%8\7J\/_ERK65__&SRI1!=-R-?^[*#
M%#:FO1!_WAG(<13/GC\\U9&,'_8,O,6.43H:G-#')OJO>OX,QDN_3>V.@1N3
M3-M7/#@XQI7IPWKLX?>^?KB'DR\XX!-O^\5JT)BU<12&L7)KZ+\;/#C5S_&>
M>-L;?E-8^T/Q4VJR-!'G000Z*AI$@3A-DES&\$&2&_$!Y$$4T^'4SRT.\H/2
M@U2/91(H 3]':2C^5\( ]4P<"-#2*E#COM+BZ&"9H_Q#:0.[Y\']XZ<GXM?T
M@L>$FZLZJG+7[Y$B+?Y>'7-5"&_T?0X.+_5"9[L/[A\\WC]I_OO&X,@C,Z+#
M42:A^)#K"1RD(AV(;*1(9!ICKQQ$41+"M<^/'A=[N?V%W45V.^W@WO&O^MJI
MV*]-Q:/Z5!RB&F_ND%<IO+ F?2E&T@CEI@2L!)R!^5<T]]?6@_M'CT[P1_IA
M>]?-Q+=8[_:7%$+<Y$,O-[.G,'5?X,2!#T(1)2)4F8QBT5=Q.NT5LB3ZTJ"R
MC&=B"N:5$3#C [!.TJG9%6]3+90,1L+7$W\IJ>EZK40$WX<Y'PZU&H(9YZ8]
M3>.>F(XBN!*^@8\R^=A)<)^^D\%AIS*#?X2'"P6J.D*#:2)1>4=P'F1F*2NU
MA(4:9*#.<&H4['>WS]MF'"1]/(ZR3"E<3:7!0%4\OQ.E ]@.<E@HB@DL OP@
M,S&-8EQVF%HX0=,\PR7F18 GT'=G] "0!) 4V$/V2; &LP?WGQX>/#DQ^(!B
M/'!]EHIW<=J'G78N8V5ZXC1$TQ>N?R-U NK$X!N(\Y'4JB=^SN%"\4I.H@RO
M"%*M JG#'BFX"*1 9B";">D\&/X_L(.C;":&J8S710@^51?1K5E?95.E$K'_
M \W5P?'^#[N"OBMGY&" XB.]YZ\Z[[E$& 6[B;RK*($%PYUJ#)A$\(=RHY(0
MT";_"7TP98QXI]-\TA,?U1#OC,_]/8FRJH!$ND4D^.]:F8D*LNA"E4N]3LOX
MRK/XQ7N9P'J29)_/8(.,>6E YZ4!+ WOWI9E@3TQ3L$CQH_'= ]M4*>F0EW(
M.$=E:_=]L09.!#P-*G(P!K1=EW$Y%%S30H/T2A'PKNW5]<I6BRQNMSRT4!F?
M2,573^2*0NJZD+]Z.@6Y*51471_N-NWF10;-*IM!G^QQ_! TK37X(MI2Y,/X
M&AF^ ;L9#E^#>A/689;FVO\3_(]/=F]J17\F)CJ]B/ 5X<NXIK@_?>>TF&H0
MA$A=**>-[7-95R<P8U&(ZUF1O/[?O.&7N\WO@CV,@A#P00E7A6B4A;S.N%OM
M!H)#5>2&[&%0U<,1'NJ%08<?AFK@S#[\.QS5QJ!3![^?HE# P7'VG]W+30&&
MON9.W*UZ3G-<)S(A([(<R'%RXH_"W3'H59:$O]*<UK(PC4$;%%L:U+]=6UIS
MW+JRH2-%-$#M('!_F\&,#&VKK]G$1V6@O&D+= 12%DGRM+^E?J5PJK\[=PZ>
MWO+TXFES^/CDMDV$D\H\'#S:/<;W+M8Z0K\*EA)LKSR&%7PSGL3I#.Q]7.!$
MO'&R<(;Z/I$<BR^^!>OV;+-N2UBW),W*?8J;,4!'S6#4RME@>(0:])6JARZ&
MA-VF="?M5I[$:(?CWZ8:_;W$:G]G;=%%&H_TH99C]//A\#?@PT_0I,L\/8'/
M $W13[,1GQWU:^EHL7ID>R- JR! 346/4I&2:BAMM_I"7DV(6B3A9J4(_[21
MI-N5)-0L,;AU E8H5M* 53A-Q2"'<Q^<R6Q$:U^<(>=*7T1@*H2YCJRGV?"R
M5L*<7WU;C0*E7]1X KO8GL5LM!=[.JH<V,67>LY&NXJEER:X1^$+7<%"L44>
M_1>)XM #5SN0X"[0<X*13(88)^)$OL%-W'>!GSS!8-P<>=CN<?@"[S26L\Y1
M8M@(=0-'GS#$;#H]^=ZMAVE8;80JL$F#YW1"X[?NO60OF5PKF=U^_(C7Z,:W
ML1!G+6(V8 7.BU11]CV;:2GB,"2G<*ST^!B:1J8,08*TXJV[UK>,/WORP'%$
M"EW40M?1V)YX7D[ "NN"5_PT BG#B"><2).1"%/8@WBNRLD$]@N,,DF3G?HN
M;3K!J^/J=ONZ+:&U:VE-^\#C1S B-\O/M8HE6AB=>!>;EM\O+Y%]D\9YUGV)
MEZ/'Q5;ZAM3SY<Z4>I[8^W>DRQ-DJ';Z6LG/.Q(S,L]E/)4S4WV/#21H PG:
M0((VD* -).B.0()6P7^89X^^N8Y748G?WJ+QVHD708N.\2 +?)T>?<%9C-+E
M165;,M%!3(IO"\P[PY9":[9B5)*=*?E2-#XQ$ <"W2MSH VCU%HV9%9V6,(4
M",'AYC%8K3!XL#(U; \,SBPTAF7;$.]62K-MQ;P)G^3:Y)B;! DHDE)_,+JA
M#5'4E>3PL\D>S*CE\:J$&Q7;"3/J5_&]VWV/TSCV9<24^(V*5+'8V4RJB^,Q
M$@KSMC X3[UV.?>[WV&$9)Z&^[7%*UN6 EMM#9:E")^R>DPYG!5(4IQ37C\E
M,P?\9_?9RBFXC4[X1CIA=:,8?W0&,<XS-3&TXUY;"4 A]J?LN]-SB&?V5GR!
M='8(?C4_;W"6OGE"_AO.4T,N%IP'*!;BMT2Q;5\ XBN (T*&]JI T2('Y>#@
MU6UR#NZ?^DZGL%W4?J,,7%_!*RKQ7FHX2 Z.29LM1 ^3!*KNJ2T1@5[9P4-3
MN>][E>DHX&FO+D2W3B1%WGH3K2X/**9'RBY4L7U*[65A7"E&@G5ZH19)R9Q4
M1?6\-J"CX0O9B"+6!=Y6F&"DPCQ6;:;: FS:JF+F5D(K?)JFK!5 ;J3)=16K
M6 &UBD]D+%5B*W<))WBMH@'>]CY^N 25#J($KHMJR$ZM#!A_W5NZ-NDTGB^9
MXH.,-TL=ILPZ8HKE(PS[5UU;-DS!)Y %>@'&@DD&PJ0[N+E[FIV :AU!QY,C
MV*\6HXYWJ:BYIFJ"L?WD%T9<X_7L,H"D#L2;+RK(R<;[;3"( F6M@;'\C"8S
M:#"8 UA1AES8=RSFI2>"-#&1H1'0>RS09#UOIDXGDS@** 7QH5$MTFI<PX6N
M;*0_JX!+).-*6O;8/-TO/S/Z&&'-09#F239O8D F:]-!:K] P@QDD*7:(F)K
MTP3JF#+9D0FTXH1FJ-38\ DP@>V'CEK+YG G!-9*M,[7HJ-A#(<6SMH5%ZJQ
M S16:R4\S5P"#[.FX50)U%6GOE'8PX]XB%AQ\'^,VR[_YD,<AB+$G /B>J;2
M2A\K(ZVLN7EJZS(ZYO@NG2"?;D8G60TS2J=7EDLS2O,XI&"!G?;0JWJIEB.Q
MG<DE2:91BH21#_3A\3LN?5VM3QKB;LJ:%4JRW.5EL=(=TF)V9KT2L985ZI[T
M=4<.'&Z0 QODP 8YL$$.;) #&^3 ZB$'[KWTK*)%<;=:J7B;'5"886C<U(P!
M##;:DO M-$M:BI:W.[,_^$!.7\W-P>!]JWF8J^==$.HZ9^Q(*8+E[(8MIUA)
MK,ZQ0^R\BMZ+:E]55\6V9T79^U_72*6(!-[CH6FU3^<XH29E2[*X!8^<0-LC
M"<_#&;ZE*/@J.S_IM)4, :3GM%L(:&8+6#%-)ZUT#6Y?N/EV.] 7I4""N[A5
M<N:%B>^>M_TVS35KW]=%W-#G+'CH5YG/S09^Q\[W;TG0K4@BXZ<&%_!S]%!
MF9^#(J!C\DA=6*_E[DY%DS/EN$%<<*^;M\(%N$KF"ED_4=J>Y@*LEL,"OUHG
M)U@7;I W_CPT0_$U*H\Z'X<M(\4:!UAP#!W4^#QH/2^[FAC7@8_@O"K/Z9X8
MZ'2,]!YP"V3W\(A!W$A#?TAKLFYH.S4FJP#'Z&))&>MC7#T,KC#%<+)<)[U:
MDN1RV)@J70I]ZU+<*'=)4X(U5V&T 8/MHI*[<AEPF@DY(R%_C9L*-D6/Z5 X
MBP5KD'*AK=3.)FO -3K3:/4ONU71JK2:79:D/11(PN#M7S^N!S+#\<#*NQ9
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MT<8*AEWT>I0S926KX0*5DVGYX,/^_,-!>\:8(!HO2^7HS=,^A49E*D(O8TQ
M^BL[RUCO$ECO#7S$WMMC]C$+AA?NGO?+7O(.=UK]]^22<E:>2MDE?S]P*R;Y
M:I?]"&.#UB1B,,29%RBJ6(N(30!:_ITHDZ>V?!%W[%\JOG$?<7[O6?9RV_'+
MR=79R3_8SX'JX+X5 8A3U+)NA&E0$"U+I6F@)%&@B6ZVW]C2!)<*@\J>IL'3
M/6[N%*KXP*L\9G#9]/7W43%HG",)D".]!U?46F.^\)PM>D39#-;=!L13\3,
MD=,A"Q445?;!E*24%<S'>[9-70JN+V)3RVX7[",J''*6,*41EX%0E@AX;G.=
M"I<6I,>N.9>,BMJ7P!Z&]"I !]0FRS11U/3'P=FB\E0=M>:71?#+Y#Y\"3SS
MXO6$@&M3JBQ42\$58]>Y%!3@HWL^B )A4Q:?P2OCW+[E0@=7C6<V]!TL^I]V
M]IM@.T=8*88+G=<;IG<1-/UII[G?0I&;0Q;E]E8Y0JNEFWWK;FODK935&XO.
MD WX38ITY4;4GVB^FVX$,,:3]"/>O"$';)X.;GF4F_R#51)@[C&ZG6(SQ/=3
M<MGF;NO'-TW&T!/A%?PN4D\DH7[7%2WGJ%9SH5'O^0SL34OOOUH.2"U62_#5
M\[?-[&XK)-854SM7S[DV&K[P1K]R=*-\;\?.;$OT#)#YD./1$NH1!1&-BF$?
M.5SF!(]Y>(,!'GB&XN@XQ0&_IS@?F*,NY <H[(&A3 !LC509LUCH"-WMMP^M
M_*)K7NH,B#H#HLZ J#,@EAF@[)JTU D1$R;22(.1J7 OQB5+F[2 _F<[P.0U
M2H]![K(0DJM0[V82&F<"TOE[!)1&GFICVF+Z&Y>X=UB6?@=#RT&/P;? "!G1
M"C0C?:+Y1]2#G1U[,]PT A'[!]']8Y"MO?LNNB_KL?9L[$;)@FE18FK%QR("
M:2NP 'X*U]D8>2;9%7JT4;1W60C;6&O8VHV4\S#-!DN3[_HJ&!D06,E9[ZEJ
MIPU':QQP.^=E&AP9S5/A+?Y2A64Y.2M:*%E<@R\5:Y!GW\RIQ]D@,M)N B)>
M37%PD8!?2PA8W9S+H2O#%B")?BQ(KAXKSNX:(MH^HVO(]HLH$W#6EF#MQ2;6
M[S\IK[Y$"CQS6CVV$0'4V-_+63K3)3(HWQR3 &\8>;7@NB@63N-CA[NK0NYX
MN;$32^Y<M"T:79>465/^7=>HBC[D8&1+]C':0H?F0CERUG6V/L8V]7-HH[>Q
MW<I^;J?.QDW8=?DOY_+!+;.,^=N4KE]3;8/5\BHZ1A8%V>XE<0S[*1C.UXS2
MXZ'-Z$QL)Z^3*,+&'_?LA'%CN(==O! _C5IN0JUES55<EE^Q9=%\ABE%A$*7
M0UN6 )D*KD1;"W@TG1W=% 4[!)6)U5/C'E*:*+PY%U4'(NX)JR#H)+Z5M];J
MLE$HZPN(Q8!C)[(YN@_5W/_02O&Y\H-IE33UA&M@D)RJ8?Z=R)B<,XW":!1%
ME+;_YTSVXG@0=9;I2%W.,(6H9A4SD6(Y._36'+4V'(7CEW..B_Q,7J"G6*#"
M'ECP4=(!XQ;$BHFY[ZK$IO.B+=YX'#\^C3=&.CCMH5FS5&[YH@PN/'G>TH K
MVGX]19YG.2\S>0*,,*JC 7(&V.@Y(V;AWBOJ3%IH?7B5>OYH;':I5)PY:ESN
M#XR?:!,/V6G M48W@#5'LD<W?[XXO7I3[+KY0)G$9NX@HV@:?"KMA;AA-X"U
M/+/",=;!(SJ$ULA6H7:M%?.VA]3))DWGD.8)G#6',E+)/B_!MKBHS%RX=!5K
MYX6*M5-78K5:F.ORIZ@A/YC%6$ *?&;ZKM".VKJZ^#4=&5#($#J%<6,5-!"Y
MJFK2"KT]*5<\J_Z;5M/)-B>B:=.:"]91[CK*74>YZRCWBX=94FT+1=KY02MT
MO@!)% +<\@PFQ-.3;A>D#3=BHBTZJCBY#]Q5G\-M'>L+'UW+W8;M-]MEZ!T%
M6$;]8#J&3Z\#9F(.$5*LC8<I%+[>3X3U=W#;3?Q,:F[%ZZN)^,W'":ZY@35?
M\D6U^M[X;MRA(S#<@L_0.>$I+-!(5QQ8P5-AZ,K):=* 1L 4^!$-NY2-PD+B
MJZC#=Z9*4.\#4B60?51B INJ@=SSLD[*6$56*YYY@44+ UP%2G#0TKLI6 <J
MY*PK?3![!/8#P)J9CJ;"JM*>T.2C=-:!+V"U\_[%&:/Z4_D9C#,Z<"!]C:^$
MM9V1LS \>MAB/BA.,$>RY*QUG(4 44*-=[T *.+2E7'8<P<[0TS+,*#6X:?2
MV5+ :MQ"46S%)OPT99ZOQ[=*_'"5=/YP2$P%4G3&#BXV.A,$$!//")E0\I%X
M6L(D.)B9O5C8SB%9NXD1,$-G1@<##+1J%(XEITS)J(O!,5W>0R5WTVF=6*&5
MBJ%EM3RQAV)F-3O S>FKJ6('GH5/SQP7=#P+@FCVXDF*83!3A3H9#&A_<9T2
M" >Q U2:53!,($5"IZN,[^?&V$DO+E$N;ZPC![#%4?,(AJ.F7#:=0H+[Q+S7
MI#W+%>(9LAN1W3*@\KPD3@]!>9M"FJ63Z'9=8GAQZ4;TH[C,XB;Q"8P7$Q-T
MN):%I+(EDOAYSJG(,\K<SK?N.K?-2V@S2S<1MOE#-1ZX?EUXI"*N;8Z>9'<7
M#@S!=CK_Q39A+)A=-PELMR<"1S#97)G>5+=>(\U'!"VI/ >11J$P_>[!F[4Y
M"VYDW;/E+6. R6Y8UA&,49TTLLHC&.*V#.<P1 !+'H)I"N*BEZ#$&PC0:,/>
MFI#ZPKIX\<0G4RJU"=%T+@5&;<MV8ZIL?5)3J554N)YJZSF;.#>J7KW6Q,TL
M\^\DT[O<E4K)@D96+GO+%JK27]%DKT$<W:D8LU'GDDHE$BE-':N%TG*%TNLR
M3Q>$EB4>Q._H&..>)P)!EC.&NB@B&_JO'F%G@;_GX/LZ(%@'!.N X)H$!)^>
MM;34PZK3U)(IB>O7N;K98%>)QA.4G2OH%^7GF4,H8BZP9#1"M_=X?XETH5<O
M&^5Z1 3TN3LVF">FKV**(-$)ESZV7- FSHDA'R(&W97&"%"PV!@!^O_O1>QA
M9^W\<&(Z%AX^68!(ZTJ3!;PPB[ Q$=6L."I^O#&Y:[5<? T\+$/X!]?CW<HK
M] <9EGK=\1QG2K2A1"X:RI[177ZT[<5:'6T[>JAVIB^"%4S[B]JK#W!S#2TG
M==,+&.FT)V0#SQC4\,9/NAZ,[,F 0B6X+J7\5SQ2N^+([$F-:2W7"2M@XUOA
MXAOW7@"6^ZW(=VQ>$U%L&P\7,L(9D9T&/8X!M.<<6-":%8X^MA$QO,M3H6\[
M?!>+D<NZU,^73+M,47/Q>V42XU?AJ20BB^I2P=</5TM68'GEE-:T/XL0++*
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MST["$".2>?3R\_7%Y0/%%<N9V=0^MNG9#0=[SLP%76A.&B\7# &R = (MBO
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M LX\CL,GDV#'H0ZQ#H!N-.8AKD&GDG,RD!Z.!!M4EY&1X7'V207X%7I]8&B
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M82(>[EIN,&MRVX.7??=M<?K*^>O_ E!+ 0(4 Q0    ( *>!=U.H^)1&F"$
M &[H   0              "  0    !B<W@M,C R,3$Q,3DN:'1M4$L! A0#
M%     @ IX%W4\& Z]1/ P  L@L  !               ( !QB$  &)S>"TR
M,#(Q,3$Q.2YX<V102P$"% ,4    " "G@7=3W]8*/;L(  "W/@  %
M        @ %#)0  8G-X+3(P,C$Q,3$Y7V1E9BYX;6Q02P$"% ,4    " "G
M@7=3G&\6]EX-  #[>P  %               @ $P+@  8G-X+3(P,C$Q,3$Y
M7VQA8BYX;6Q02P$"% ,4    " "G@7=3[!D#ZDT(  !:00  %
M    @ ' .P  8G-X+3(P,C$Q,3$Y7W!R92YX;6Q02P$"% ,4    " "G@7=3
MEY.M%JLD  "!(P$ '@              @ $_1   97AH:6)I=#$P,6)O<W1O
M;G-C:65N=&EF:6,N:'1M4$L! A0#%     @ IX%W4VEIQ9#7&P  6 4! !X
M             ( !)FD  &5X:&EB:70Q,#)B;W-T;VYS8VEE;G1I9FEC+FAT
M;5!+ 0(4 Q0    ( *>!=U/R=3P6@1(  $!]   >              "  3F%
M  !E>&AI8FET,3 S8F]S=&]N<V-I96YT:69I8RYH=&U02P4&      @ "  F
) @  ]I<

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
